Method and apparatus for photothermal treatment of tissue at depth

Information

  • Patent Grant
  • 8915948
  • Patent Number
    8,915,948
  • Date Filed
    Friday, February 15, 2008
    16 years ago
  • Date Issued
    Tuesday, December 23, 2014
    10 years ago
Abstract
The present invention provides method and apparatus for treating tissue in a region at depth by applying optical radiation thereto of a wavelength able to reach the depth of the region and of a selected relatively low power for a duration sufficient for the radiation to effect the desired treatment while concurrently cooling tissue above the selected region to protect such tissue. Treatment may be enhanced by applying mechanical, acoustic or electrical stimulation to the region.
Description
BACKGROUND

1. Field of the Invention


This invention relates to methods and apparatus for the photothermal treatment of tissue and, more particularly, to methods and apparatus for photothermal treatment of at least a selected region of tissue located starting at a depth at about the boundary zone of dermal and subdermal tissue and extending therebelow.


2. Description of the Related Art


The benefits of being able to raise and/or lower the temperature in a selected region of tissue for various therapeutic and cosmetic purposes has been known for some time. For instance, heated pads or plates or various forms of electromagnetic radiation, including microwave radiation, electricity, infrared radiation and ultrasound have previously been used for heating subdermal muscles, ligaments, bones and the like to, for example, increase blood flow, to otherwise promote the healing of various injuries and other damage, and for various therapeutic purposes, such as frostbite or hyperthermia treatment, treatment of poor blood circulation, physical therapy, stimulation of collagen, cellulite treatment, adrenergic stimulation, wound healing, psoriasis treatment, body reshaping, non-invasive wrinkle removal, etc. The heating of tissues has also been utilized as a potential treatment for removing cancers or other undesired growths, infections and the like. Heating may be applied over a small localized area, over a larger area, for example to the hands or feet, or over larger regions of tissue, including the entire body.


Since most of the techniques described above involve applying energy to tissue at depth through the patient's skin surface, peak temperature generally occurs at or near the patient's skin surface and decrease, sometimes significantly, with depth. Further, while microwaves or ultrasonic and other acoustic radiation have been used in the past for certain heating treatments at depth, as disclosed in, for example, U.S. Pat. No. 5,871,524 to Knowlton, U.S. Pat. No. 5,769,879 to Richards, et al., U.S. Pat. No. 5,507,790 to Weiss, or U.S. Pat. No. 5,143,063 to Fellner, since such radiation, particularly microwaves, are potentially mutagenic and can otherwise result in cell or systemic damage and, particularly for acoustic sources, are relatively expensive, and may not be practical for large-area treatment, these techniques have had limited use for the heating of tissues.


While optical and near infrared (NIR) radiation (collectively referred to hereinafter as “optical radiation” is generally both less expensive and, being non-mutagenic, safer than microwaves radiation, the use of optical radiation has heretofore not been considered suitable for most applications involving heating of tissue at depth, the term “tissue at depth” as used herein meaning tissue at the border zone of the dermis and hypodermis, some of which tissue may be in the lower dermis, mostly at a depth deeper than 1 mm, and tissue below this border zone to a depth of up to about 50 mm The reason why this radiation has not been considered suitable is because such radiation is both highly scattered and highly absorbed in surface layers of tissue, precluding significant portions of such radiation from reaching the tissue regions at depth to cause heating thereof. In view of the energy losses due to scattering and absorption, substantial optical (including NIR) energy must be applied in order for enough such energy to reach a region of tissues at depth to have a desired effect. However, such high energy can cause damage to the surface layers of tissue, making it difficult to achieve desired photothermal treatments in tissue regions at depth. For these reasons, optical radiation has heretofore had at most limited value for therapeutic and cosmetic treatments on tissue at depth.


Further, while heating of tissue at depth alone is useful for many treatments, there are treatments, for example to relieve pain and stiffness in muscles or joints, where heating in conjunction with massage or other mechanical stimulation, ultrasound or other acoustic stimulation or electrical stimulation of the tissue may also be useful.


Thus, a need exists for improved method and apparatus for photothermal treatment of tissue regions at depth, and in particular for treatment of subdermal regions of tissue, and for method and apparatus for combining heating with stimulation in such regions for various treatments.


SUMMARY OF THE INVENTION

The present invention generally relates to methods and apparatus for photothermal treatment, both therapeutic and cosmetic, of tissue located at depth in a patient's body, as this term has previously been defined. Optical radiation utilized in practicing the invention is at a wavelength or wavelength band which is neither highly scattered in the patient's skin nor highly absorbed by water in tissue so that the maximum quantity of such radiation can reach the treatment region at depth. The wavelength utilized typically is between about 600 nm and about 1850 nm, more preferably between about 800 nm and about 1350 nm, and most preferably between about 1050 nm and about 1250 nm. Other potential ranges for certain depths of tissue are set forth in Table 1. The longer the wavelength, the lower the scattering; however, outside of the indicated bands, water absorption is so high that little radiation can reach tissue at depth. While the tissue to be treated may be a chromophore at the wavelength(s) utilized within the above bands, this is not a limitation on the invention, and absorption by water, and to a lesser extent fat or lipid, in the region is generally sufficient to achieve the desired heating. In some applications, absorption at certain wavelengths can be increased by delivering a suitable chromophore to the treatment region. The optical radiation source utilized may be a monochromatic source, such as a laser or light emitting diode (LED), or may be a wide spectrum source such as a halogen lamp or arc lamp. Where a wide spectrum source is used, filtering or shifting of wavelengths outside the above bands may be performed. The source may also be a pulsed source or a continuous wave (CW) source. Natural light sources such the sun can also be used to practice this invention. Where the source is a pulsed source, the source typically remains over a treatment region for the duration of each pulse, or a train of pulses may be applied. Where the source is a (CW) source, it is typically moved over the surface of the patients skin at a selected rate, the rate of movement determining the dwell time over a given treatment region.


The invention also requires that cooling be applied to the patient's skin surface concurrently with the application of optical radiation thereto. While the radiation reaches the tissue at depth to be treated quickly to begin the heating thereof, cooling propagates as a cold wave protecting tissue above the treatment region and moving the depth of maximum heating further into the skin. Ideally the cooling wave propagates to a depth just above the treatment region, but does not extend to the treatment region at least until sufficient energy has been delivered to the treatment region to effect the desired treatment Cooling may also be applied to the patient's skin prior to the application of radiation thereto to more effectively protect tissue above the treatment region and to more rapidly result in maximum heat being at or near the desired depth. This may also permit higher energy and shorter duration for the radiation source. The head used to apply the radiation may also be used to apply cooling.


Another feature of the invention is that the radiation is applied at low power for an extended time, the time varying with the depth of treatment and with the treatment being performed. For example, the time may vary from approximately 2 seconds to approximately 2 hours for depths of approximately 1 mm to 50 mm respectively. Depending on depth, the treatment being performed and other factors, the power density may vary from approximately 0.2 to 50 W/cm2, more preferably from approximately 0.5 to 20 W/cm2, and most preferably from 0.5 to 10 W/cm2 or 0.5 to 5 W/cm2.


Other advantages, novel features, and objects of the invention will become apparent from the following detailed description of the invention when considered in conjunction with the accompanying drawings, which are schematic and which are not intended to be drawn to scale. In the figures, each identical, or substantially similar component that is illustrated in various figures is represented by a single numeral or notation. For purposes of clarity, not every component is labeled in every figure, nor is every component of each embodiment of the invention shown where illustration is not necessary to allow those of ordinary skill in the art to understand the invention.





BRIEF DESCRIPTION OF THE DRAWINGS

Non-limiting embodiments of the present invention will be described by way of example with reference to the accompanying drawings in which:



FIG. 1 is a schematic diagram of one embodiment of the invention, as applied to a tissue sample;



FIG. 2 is a schematic diagram of another embodiment of the invention, showing an internal design configuration;



FIG. 3 is a schematic diagram of another embodiment of the invention, showing another internal design configuration;



FIG. 4 is a schematic diagram of another embodiment of the invention, showing another internal design configuration;



FIG. 5 is a schematic diagram of another embodiment of the invention, showing another; internal design configuration



FIG. 6 is a schematic diagram of another embodiment of the invention, showing another internal design configuration;



FIG. 7 is a schematic diagram illustrating a plurality of devices of the invention being used in conjunction with each other;



FIG. 8 is a schematic diagram of another embodiment of the invention, showing yet another internal design configuration;



FIG. 9 is a schematic diagram of another embodiment of the invention having a different configuration;



FIG. 10 is a schematic drawing of a model of tissue, used in certain calculations;



FIG. 11 is a plot of the temperature produced by an embodiment of the invention in a tissue sample versus tissue depth;



FIG. 12 is a plot of a temperature relaxation profile produced by an embodiment of the invention in a tissue; and



FIG. 13 is a plot of depth of heating vs. treatment time as determined using Equation 12.





DETAILED DESCRIPTION

Applications in which the invention may be useful include the treatment of various diseases, particularly, cellulite and subcutaneous fat treatment, physical therapy, muscle and skeletal treatments, including relief of pain and stiffness for muscles and joints, and treatment of spinal cord problems, and treatment of cumulative trauma disorders (CTD's) such as carpel tunnel syndrome (CTS), tendonitis and bursitis, fibromyalgia, lymphedema and cancer therapy.


More specifically with respect to cancer therapy, hyperthermia resulting from utilizing the teachings of this invention may be utilized to treat various skin cancers including, but not limited to, basel cell carcinoma, squamous cell carcinoma, lymphoma and possibly treatment (palliative) of melanoma. Hyperthermia may also enhance the efficacy of radiation, for example x-ray, therapy, chemotherapy, therapy with immunmodulators such as ALDARA or PDT therapy. Such combination therapy may for example reduce required treatment time.


The tissue to be treated may be a collagen-rich tissue. Collagen-rich tissues that may be treated include superficial cortical bone, synovium joint capsules, tendon sheaths, menisci, myofascial interfaces, periosteum, fibrotic muscle, or major nerve trunks. The device may also be used for reshaping procedures such as non-invasive wrinkle removal through stimulation of collagen production in a subsurface region of tissue. Heating of the subsurface region of tissue to a temperature of between 37.5 and 45° C. may stimulate generation of new collagen and/or elastin. For example, expression of HSP70 (“Heat Shock Protein”) may be stimulated when the tissue is heated to between 41 and 42° C. for between 20 and 30 minutes. Other proteins, cytokins and/or growth factors may also be stimulated or released in response to heating. Significant new collagen deposition, formation or rearrangement may be possible, which may improve skin appearance or texture, allowing wrinkles, fine lines, scars, stretch marks or other indicators to be removed. In general, there exists a relation between the temperature reached and the time of application that is necessary to stimulate new collagen deposition and prevent irreversible damage. Additionally, multiple treatments may be used in some treatment modalities.


Hypothermia resulting from utilizing the teachings of this invention may also be utilized for hair growth management, and for treatment of psoriasis, scars, rosacea and various conditions of toe and finger nails. For hair growth management, which includes temporary and permanent hair removal and control of hair growth, a dermal or subdermal temperature rise of a few degrees, for example to 42-45° C. can produce an anagen effluvium. This could be particularly useful for hair grow management on hairs containing little or no melanin, for example gray, white or blond hairs. The efficacy of such treatment may be enhanced by using wavelengths absorbed by melanin or by performing the treatment in conjunction with other hair removal techniques. Hypothermia may also be used to treat psoriasis, including psoriasis plaques and nail psoriasis. The teachings of this invention may thus be used to treat psoriasis, either alone or conjunction drug treatment, light treatment, for example with an excimer laser, flashlamp, uv or pulse dye laser, or other existing treatment. Scars, having different crosslinking and different denaturation thresholds then normal tissue, may be treated by hypothermia to, for example, reduce turnover, turnover being significantly enhanced for scar tissue. A special handpiece with an aperture adjustable to the shape of the scar may be desirable for treating scars. Hypothermia induced in accordance with the teachings of the invention may also be used to kill demodex mites resident in follicles which cause rosacea. Finally, hypothermia induced by this invention may be used to enhance or control growth rate of toe or finger nails or to otherwise treat conditions of these nails, for example nail fungus and dystrophic nails. The nail (matrix) is relatively accessible to light treatment. The nails can be cooled by emergence in a water bath and exposed to the light. The mechanism for enhanced nail growth may be enhanced metabolism, blood supply (vasodialation by heat and light) or biostimulation.


The application of thermal energy to tissue may also be used, for example, in physical therapy treatments, such as to enhance or accelerate wound healing or relieve pain. Beneficial effects may include a decrease in joint stiffness, an increase in joint extensibility of collagenous structures such as tendons and scar tissue, pain relief, blood-flow changes, or a decrease in muscle spasm and increase in muscle tone. As another example, large protein molecules may have high absorption coefficients, and the heating of protein-rich collagenous tissues may contribute to healing. A wide variety of conditions may be treated using this invention, for example, but not limited to, strained tendons, tenosynovitis, torn ligaments, tendonitis, bursitis, torn joint capsules, or torn muscles. As yet another example, other processes may be activated or deactivated within the tissue during heating. For example, heating of the tissue may be used to enhance or modify the activity of a pharmaceutical or another bioactive substance or to facilitate the delivery thereof through the skin. Mechanical or electrical stimulation, such as massage, may be used in conjunction with heating to achieve benefits greater then can be achieved by either alone. Pressure may also be applied to the skin surface above the treatment region to facilitate the treatment.


In another example, when tissue is heated to greater then the damage temperature of the tissue, irreversible changes to the tissue may occur, up to and including cell death, apoptosis or the like. The damage temperature is the temperature by which cells, collagen, or other tissue components may be irreversibly damaged. The damage temperature may be useful in certain therapeutic situations, for example, to damage unwanted cells or other structures, such as collagen, malignant or benign tumors, hair bulb, deep pigmented lesions or fat. Further, by heating tissue to a temperature above the body temperature (typically 37° C.), but below the damage temperature, it may be possible to change the dynamics of various biological processes, such as metabolism.


Where the tissue is a tumor, it may be desired to use heat in accordance with the teachings of this invention to kill the tumor, or at least a portion thereof, such as a necrotic center. Where the tissue is an artificially created tissue, such as a tissue-engineered scaffold, preferential heating of the center of the artificial tissue may be used, for example, to stimulate cell division within the tissue, to promote cell division or cell growth within the artificial tissue structure.


In certain embodiments, the present invention may be used for non-invasive or non-destructive reduction of localized fat deposits. For example, the invention may be used to heat fat or adipose cells past their damage temperature, causing cell damage and/or necrosis. Alternatively, the treated cells may undergo apoptosis, resulting in cell death. The dead cells may then be removed or resorbed into the body, for example, by the body's phagocytic or lymphatic systems. Fat reduction may also be achieved by heating fat or adipose cells to an elevated temperature, but below the damage temperature. For example, the fat cells may be heated to a temperature of between about 41° C. and about 45° C. Under these conditions, applying heat to subcutaneous fat may activate lipases or metabolize lipids contained within the adipose tissue found within the subcutaneous fat layer, or blood flow may increase to the heated area. Additionally, “lipolysis,” or the process of breaking down fat in the body, may be regulated by enzymes sensitive to temperature, such as HSL (“hormone-sensitive lipase”). Thus, elevating the temperature of the adipose cells may increase the lipolysis rate, and thus contribute to a reduction in subdermal fat in the area being treated. This temperature can be below the temperature for vascular/lymph damage so damaged fatty cells and fatty acids can be easily removed from the treatment region. Additionally, application of the present invention may be used in combination with other fat-reduction techniques, such as medication, exercise, or adrenergic stimulation Heating of subcutaneous fat may also result in increased dermal thickness. Thus, fatty tissue may be replaced by fibrous and dermal tissue, this resulting in improved skin appearance. Thermal activation of lymph systems in subcutaneous fat can also be used to treat cellulite by removing proteins from extra cell spaces.


Stated another way, fat and/or cellulite reduction may be achieved utilizing the teachings of this invention by providing an elevated (but below damage threshold ˜43-48° C.) temperature in the targeted region at depth. The mild hyperthermia initiates biological response through one or several of the following pathways:

    • 1. Increase of activity of enzymes regulating the process of lipolysis, in particular, hormone sensitive lipase (HSL). As a result, decrease of fat stores in hypodermis.
    • 2. Stimulation of blood and lymph flow in the targeted area with multiple positive consequences, including (but not limited to) further decrease in the fat stores and accelerated regeneration of connective tissue.
    • 3. Induction of apoptosis in adipocytes, with subsequent removal of residual cell material by the body's scavenging system.
    • 4. Decrease of lipid's viscosity, resulting in increasing mobility of fat globules and permeability of adipocytes' membranes.
    • 5. Stimulation and or reorganization of the connective tissue surrounding subdermal fat depots with or without concurrent changes of the dermal collagen.


The net result is a shift of balance between fat and connective tissue in hypodermis toward the latter and improved appearance of skin.



FIG. 1 shows an apparatus 100 for one embodiment of the invention. For this apparatus, optical energy 30 from a suitable energy source 1 passes through optical (for example, focusing) device 2, filter 3, cooling mechanism 4 and contact plate 8, before reaching tissue 31. A suitable optical impedance matching lotion or other suitable substance would typically be applied between plate 8 and tissue 31 to provide enhanced optical and thermal contact. Tissue 31, as shown in FIG. 1, is divided into an upper region 5, which, for applications where radiation is applied to the skin surface, would be the epidermis and dermis, and a lower region 6 which would be a subdermal region in the previous example. Energy 30, possibly in conjunction with one or a combination of focusing from optical device 2, and wavelength selection from filter 3, and with cooling from mechanism 4, results in maximum heating occurring at a selected depth in tissue 31, which depth is, as previously indicated, at or near the junction of regions 5 and 6 or in lower region 6 for this invention. In some embodiments of the invention, certain of these components, such as, for example, filter 3 where a monochromatic source is utilized or optics 2, may not necessarily be present.


In some embodiments of the invention, energy source 1, optical device 2 and/or filter 3 may also require a cooling mechanism. This cooling mechanism may or may not be the same as or connected to cooling mechanism 4 that cools tissue 31 through contact plate 8, as indicated by arrows 32 in FIG. 1. For example, in the embodiment shown in FIG. 1, cooling mechanism 7, shown separately from cooling mechanism 4, is used to cool filter 3. Energy source 1 may be any suitable optical energy source able to produce optical energy 30 at a wavelength that produces heating within tissue 31 at the depth of a desired treatment region. The exact energy source, and the exact energy chosen, may be a function of the tissue 31 to be heated, the depth within the tissue at which treatment is desired and of the absorption of that energy in the desired area to be treated. For example, energy source 1 may be a radiant lamp, a halogen lamp, an incandescent lamp, a arc lamp, a fluorescent lamp, a light emitting diode, a laser (including diode and fiber lasers), the sun or other suitable optical energy source.


Energy source 1 may produce electromagnetic radiation, such as near infrared or visible light radiation over a broad spectrum, over a limited spectrum or at a single wavelength, such as would be produced by a light emitting diode or a laser. In certain cases, a narrow spectral source may be preferable, as the wavelength(s) produced by the energy source may be targeted towards a specific tissue type or may be adapted for reaching a selected depth. In other embodiments, a wide spectral source may be preferable, for example, in systems where the wavelength(s) to be applied to the tissue may change, for example, by applying different filters, depending on the application.


As previously indicated, in order to minimize both scattering and absorption of the applied optical radiation, the optical radiation produced by energy source 1 should be radiation with a wavelength which is minimally scattered and absorbed, the available wavelengths decreasing with increasing depth as generally indicated in Table 1.


Certain wavelengths may be preferentially absorbed by the tissue to be treated. As one example, if the tissue to be treated includes subcutaneous fat, certain wavelengths may be absorbed more effectively by the fat or adipose cells than by the surrounding tissues. For example, optical radiation having wavelengths around 925 nm, 1206 nm, 1730 nm and 2300 nm may be desirable (see for example copending application Ser. No. 09/277,307, which is incorporated herein by reference, for suitable ranges); however, only the lower three of these ranges would typically provide sufficient penetration for use in practicing this invention. Using electromagnetic radiation of these wavelengths, the coefficient of absorption by this radiation in the lipids, and in particular the triglycerides located within the adipose tissue may be greater than that of the absorption coefficient of these wavelengths in water. Thus, these wavelengths when applied to a tissue sample, will preferentially be absorbed by the fat tissue, thus resulting in the preferential heating of this tissue. The selective heating of the fatty tissue can be enhanced by the lower heat capacity of fatty tissue vs. aqueous tissue. Also, the decreased blood perfusion of the subcutaneous fat vs. the dermis can be used to enhance selective heating of the fatty tissue. Compression sufficient to reduce blood flow within the target area can minimize unwanted heat convection, and therefore heat leakage, from the target area. The compression to the subdermal target area can be made selective by forming a skin fold and applying skin pressure sidewise. This results in compression of the subcutaneous fat and of skin outside the field of optical exposure. The skin on top of the skin fold, which skin is exposed to the optical radiation, is not compressed, and therefore the blood flow therein is not appreciably reduced so long as the length of the skin fold does not exceed a critical length. Blood flow within the part of the dermis exposed to optical radiation can help to remove unwanted excessive heat in this skin component.


Where optical device 2 is a focusing device, it may be any suitable device able to focus at least a portion of energy 30 arriving from energy source 1 at tissue 31, and in particular at a selected depth in tissue 31. For example, device 2 may include mirrors, prisms, reflectors, lenses such as Fresnel lenses, collimating lenses or focusing lenses, diffraction gratings, or other optical device.


Filter 3 may be any suitable filter able to select, or at least partially select, certain wavelengths or wavelength bands from energy source 1. In certain types of filters, a specific set of wavelengths may be blocked by the filter. It is also possible that undesired wavelengths in the energy from source 1 may be wavelength shifted in ways known in the art so as to enhance the energy available in the desired wavelength bands indicated above and in Table 1. Thus, filter 3 may include elements designed to absorb, reflect or alter certain wavelengths of electromagnetic radiation. For example, filter 3 may be used to remove certain types of wavelengths that are absorbed by surrounding tissues. For instance, dermis and epidermis tissues are primarily composed of water, as is much of the rest of the human body. By using a filter that selectively removes wavelengths that excite water molecules, the absorption of these wavelengths by the body may be greatly reduced, which may contribute to a reduction in the amount of heat generated by light absorption in these molecules. Thus, by passing radiation through a water-based filter, those frequencies of radiation which may excite water molecules will be absorbed in the water filter, and will not be transmitted into tissue 31. Thus, a water-based filter may be used to decrease the amount of radiation absorbed in tissue above the treatment region and converted into heat.


In other embodiments, filter 3 may be combined with other elements of the device, for example, cooling system 4 or cooling mechanism 7. Thus, water may both attenuate energy 30 arising from energy source 1, as well as cool the contact plate, and tissue in contact with the contact plate, or various other components of the device. More than one filter or filter type may also be present.



FIG. 1 shows a cooling mechanism 4 adjacent to the surface of tissue 31. Cooling mechanism 4 may be any suitable cooling mechanism able to reduce the temperature of tissue 31. Heat energy 32 may be drawn from tissue 31 across contact plate 8 into cooling mechanism 4. For example, cooling system 4 may be air or other suitable gas that is blown over contact plate 8, cooling water, or a cooling oil or other fluid. Mixtures of these substances, such as an oil and water mixture, may also be envisioned. Cooling mechanism 4 may have any suitable configuration, for example, a flat plate, a series of conducting pipes, a sheathing blanket, or a series of channels for the passage of air, or other gases, or liquid across plate 8. For example, in one embodiment, cooling system 4 may be a water-cooled contact plate. In another embodiment, cooling mechanism 4 may be a series of channels carrying a coolant fluid or a refrigerant fluid (for example, a cryogen), which channels are in contact with tissue 31 or with plate 8. In yet another embodiment, cooling system 4 may comprise a water or refrigerant fluid (for example R134A) spray, a cool air spray or air flow across the surface of tissue 31. In other embodiments, cooling may be accomplished through chemical reactions (for example, endothermic reactions), or through electronic cooling, such as Peltier cooling. In yet other embodiments, cooling mechanism 4 may have more than one type of coolant, or cooling mechanism 4 and/or contact plate 8 may be absent, for example, in embodiments where the tissue is cooled passively or directly, for example, through a cryogenic or other suitable spray. Sensors or other monitoring devices may also be embedded in cooling mechanism 4, for example, to monitor the temperature, or determine the degree of cooling required by tissue 31, and be manually or electronically controlled.


In certain cases, cooling mechanism 4 may be used to maintain the surface temperature of tissue 31 at its normal temperature, which may be, for example, 37 or 32° C., depending on the type of tissue being heated. In other embodiments, cooling mechanism 4 may be used to decrease the temperature of the surface of tissue 31 to a temperature below the normal temperature of that type of tissue. For example, cooling mechanism 4 may be able to decrease the surface temperature of tissue 31 to, for example, a range between 25° C. and −5° C.


In some embodiments of the invention, such as shown in FIG. 1, energy 30 from energy source 1 may pass through cooling mechanism 4. In these types of configurations, cooling mechanism 4 may be constructed out of materials able to transmit at least a portion of energy 30, for example, air, water or other gases or fluids, glass, or a clear plastic. In other embodiments, cooling mechanism 4 may be formed out of a series of discrete channels, and energy 30 may pass between these channels. In other embodiments of the invention, energy 30 may not be directed through cooling mechanism 4. For example, in the embodiment shown in FIG. 8, energy source 19 and cooling system 18 may be positioned on opposite sides of chamber 17.


Contact plate 8 may be made out of a suitable heat transfer material, and also, where the plate contacts tissue 31, of a material having a good optical match with the tissue. Sapphire is an example of a suitable material for plate 8. In some embodiments, contact plate 8 may have a high degree of thermal conductivity, for example, to allow cooling of the surface of the tissue by cooling mechanism 4. In other embodiments, contact plate 8 may be an integral part of cooling mechanism 4, or be absent. Contact plate 8 may be made out of a deformable or viscoelastic material in some embodiments of the invention, for example, a gel such as a hydrogel. In other embodiments, contact plate 8 may be made of a solid material, such as a glass, a crystal such as sapphire, or a plastic. In some embodiments of the invention, such as shown in FIG. 1, energy 30 from energy source 1 may pass through contact plate 8. In these configurations, contact plate 8 may be constructed out of materials able to transmit at least a portion of energy 30, for example glass, sapphire, or a clear plastic, or contact plate 8 may be constructed in such a way as to allow at least a portion of energy 30 to pass through contact plate 8, for example, via a series of holes within contact plate 8.


In certain embodiments of the invention, various components of system 100 may require cooling. For example, in the embodiment shown in FIG. 1, optical device 2 and filter 3 may be cooled by cooling mechanism 7. The design of cooling mechanism 7 may be a function of the components used in the construction of the apparatus. Cooling mechanism 7 and cooling mechanism 4, in FIG. 1, are illustrated as separate systems. However, in other embodiments, cooling mechanism 7 and cooling mechanism 4 may be part of the same system, or one or both may be absent. Cooling mechanism 7 may be any suitable cooling mechanism known in the art, such as air, water, or an oil. Mixtures of these substances, such as an oil and water mixture, may also be envisioned. Cooling of the components may be accomplished through convective or conductive cooling.


One or more of energy source 1, optical device 2, filter 3, cooling mechanism 4, or cooling mechanism 7 may be electronically controlled. For example, sensors embedded in cooling mechanism 4 or contact plate 8 may determine the amount of energy reaching tissue 31, and may direct energy source 1 to produce more or less energy or may direct cooling mechanism 4 to increase or decrease cooling, depending on the application. Other sensors and the like may be embedded in any of the components illustrated herein. The controls may be, for example, electronically preprogrammed, or manually operable.


The present invention is not limited to treating a specific region or area of tissue. For example, as illustrated in FIGS. 8 and 9, the invention may be constructed in such a way as to treat an entire person. For example, in FIG. 8, chamber 17 contains cooling mechanism 18 and energy source 19. Cooling mechanism 18 may be cooled in the same ways described above for cooling mechanisms 4 and 7. Energy source 19 may contain, for example, a series of lamps or other energy sources, optionally surrounded by filters 40. In this embodiment, filters 40 are built into the side of chamber 17. FIG. 9 shows another design, where chamber 17 has a cooling mechanism 18, but does not contain an energy source. Instead, energy 42 from the sun 41 or another energy source, such as an external lamp, is directed to chamber 17, for example, directly, by means of reflectors 20, or by means of a lens such as Fresnel lens 19. The patient may be cooled within the chamber by air flow or other suitable cooling mechanism 18.


In FIG. 2, another embodiment of the invention is shown. In this embodiment, a lamp 9, for example an incandescent lamp, is used as the energy source. Lamp 9 is surrounded by a specially coated reflector 10 to maximize light delivery efficiency to the treatment region of tissue 31. A fluid 13 may pass between contact plate 8 and filter 3. Contact plate 8, cooled by fluid 13, may cool the surface of the tissue to which it is applied. In FIG. 3, lamp 9 has been replaced by a monochromatic light emitting element 11 and lens 12, element 11 being, for example a laser diode, other suitable laser or a light emitting diode. As in the embodiment shown in FIG. 2, contact plate 8 and filter 3 are cooled by fluid 13 flowing therebetween; these two components may also be cooled by flow of cold liquid gas, for example R134A, from a pressurized can. Thus, this embodiment illustrates how a monocromatic element 11 may be used as the energy source.


A different type of cooling mechanism is illustrated in FIG. 4. In FIG. 4, energy arising from energy source 1 is reflected using reflector 10 through filter 3, a transparent isolating material 16, and contact plate 8. Two fluids are used to cool the filter and the contact plate. Upper fluid 14 flows between filter 3 and isolating material 16, while lower fluid 15 passes between isolating material 16 and contact plate 8. Fluids 14 and 15, in this embodiment, may not be the same fluid; however, in other embodiments, the two fluids may be the same fluid, or have a common reservoir. Contact plate 8, in this embodiment, may be made out of, for example, a transparent or a semi-transparent material, such as a glass, plastic or sapphire. Alternatively, contact plate 8 may be formed out of an opaque material, but have openings to allow energy to pass through contact plate 8. A similar embodiment of the invention is shown in FIG. 5, where the energy source 1 has been replaced by an element that produces discrete wavelengths, such as a light emitting diode or a laser diode 11. Optional lens 12 has also been added to the system as illustrated in FIG. 5.


In certain embodiments of the invention, contact plate 8 may be absent. For example, in the embodiment shown in FIG. 6, no contact plate is used, and fluid 13 (for example a liquid, gas such as air or a spray) passes or flows directly over the surface of tissue 31. Legs 42 connected to the device may be constructed in such a manner as to correctly position filter 3 over the surface of the tissue. Legs 42 may be any component able to maintain a proper distance between the surface of tissue 31 and device 100. In some embodiments of the invention, legs 42 may be constructed out of a flexible or a semi-solid substance that, for example, may conform to the surface of tissue 31, such as a gel. In other embodiments of the invention, legs 42 may be constructed out of a solid substance, such as rubber or plastic. Legs 42 may have any arrangement underneath the device that allows for the proper positioning of the device relative to the tissue. For example, legs 42 may be arranged in a triangular or a square pattern. In other embodiments of the invention, legs 42 may be a ring or a series of bars that surrounds the area being treated or legs 42 may be absent.


More than one device 100 of this invention may be used simultaneously. For example, in FIG. 7, a series of devices 100 have been arranged into a semicircular pattern. These devices may be linked together to treat large areas of a subject's body. Additionally, the devices may be interconnected in such a way as to provide flexibility, so that, for example, the apparatus may conform to the contours of the body. For example, the device may be worn as a belt, a leg wrap, an arm wrap, or wrapped around the torso. Devices 100 may also be mounted to a chair, bed or other suitable surface for the treatment of a patient's back, thighs and/or buttocks. Alternatively, devices 100 may be used to create an array of small island areas within a larger area (see for example copending application Ser. No. 10/033,302 which is incorporated herein by reference). This may, for example, be a safer alternative to large area heating, particularly for extended treatment regimens. By optimizing the spacing between treated areas, for example, through the addition of “masks” in filter 3 between energy source 1 and tissue 31 that block portions of the energy arising from energy source 1, and/or through the use of multiple separate devices 100 as is shown in FIG. 7, treatment of the subdermal tissue may be maximized, while causing a minimal amount of patient discomfort, and/or allowing faster recovery time.


Where optical source 1 is a continuous wave (CW) or other long duration source, device 100 for various of the embodiments may be slid or scanned over the surface of the patient's skin to overlie successive treatment regions, the dwell time, and thus the treatment duration, for each such region being a function of the rate at which the device is moved The device may also include a cooling mechanism ahead of the portion of the device under source 1 to precool skin above the treatment region (see for example issued U.S. Pat. Nos. 6,273,884 and 6,511,475, which are incorporated herein by reference).


Any of the embodiments can include a contact sensor to assure good optical and thermal coupling, and systems operating in the sliding mode may also include one or more motion sensors to control radiation delivery, cooling and other functions dependent on scanning speed, to enhance system safety and for other reasons.


In addition to coupling the deep heating treatment of this invention with deep cooling to enhance treatment of fat, bone, muscle, etc., device 100 may also include a massager, vibrator or other mechanical stimulation device or a DC or other suitable electrical stimulation source. It has been found that such mechanical or electrical stimulation is more effective for hot tissue. Similarly, the effect of deep heating may be enhanced by massage or other stimulation because both heat and cold generally penetrates better in compressed skin and subdermal tissue. Thus, the combination of deep heating and mechanical or electrical stimulation may provide significantly better results then either one alone. Heating may also be enhanced by supplementing the optical heating with, for example electro-stimulation by AC/DC, or additional heating by RF, etc. Tensioning or pressure applied to the skin overlying the treatment region may also enhance treatment effect.


The teachings of this invention may also be utilized for hair removal treatments by targeting the hair bulb, which is generally located in the subcutaneous layer 6. The treatment would be done at low power sufficient to raise the temperature of the fat surrounding the hair bulb, and thus the hair bulb, to roughly 45° C. and should be performed for a relatively long time period, for example, 15 minutes. The hair bulb also contains high proliferation water cells which react strongly with the applied radiation to increase bulb temperature, leading to the destruction thereof.


The function and advantages of these and other embodiments of the present invention will be more fully understood from the following examples. These examples are intended to be only illustrative in nature and are not intended to limit the scope of the invention.


EXAMPLE 1

This example illustrates theoretical calculations corresponding to one embodiment of the invention as applied to human skin.


Initially, a model of the skin was prepared. This model included two layers of tissue possessing distinct optical and thermal properties: dermis and subcutaneous fat (FIG. 10). The presence of fine structures such as the basal layer and the vessel plexus was neglected. Monochromatic light was assumed to be incident normal to the surface. The input power density was designated as F0. Both the surface temperature (Ts) at depth z=0 and the bottom temperature (Th) at depth z=h were kept fixed at prescribed levels. Specifically, Th was set at 37° C. due to the temperature stabilization effect of blood and metabolic heat generation on muscle tissue. The objective of this example was to evaluate the steady-state temperature distribution within the skin and to find the characteristic depth zmax where the steady-state temperature reaches a maximum.


Starting with the problem of light transport within the tissue, scattering in both tissue layers predominated strongly over absorption, allowing the diffuse approximation to be applied. This approach was particularly valid within the wavelength range of 600 nm to 1400 nm, which may also be referred to as the “therapeutic window”. The one-dimensional light transport problem in the diffusion approximation for the two-layered tissue model of FIG. 10 can be solved assuming both the tissue irradiance and the light flux to be the continuous functions of coordinate z at the dermis and fat interface. The resulting expression for the tissue irradiance, ψ, obtained may be written in the following general form:

ψ1(z)=F0·τcol·[V1·exp(−κ1·z)+V2·exp(κ1·z)−V3·exp(−μt1·z)], z≦hd, ψ2(z)=F0·τcol·[V4·exp(−κ2·(z−hd))−V5·exp(−μt2·(z−hd))], z>hd,  (1)

where indices 1 and 2 stand for dermis and subcutaneous fat, respectively. κ=√{square root over (3·μa·μtr)} and μt=μas are the diffusion and extinction coefficients for light in the corresponding layers, and







τ
col

=


4


n
1



n
2




(


n
1

+

n
2


)

2







is the attenuation coefficient of the collimated light at the surface. Flux amplitudes V1 to V5 were determined by the boundary and interface conditions. In particular, if the coefficients of refraction of both layers are the same, the interface condition at z=hd is such that both the radiance and the total light flux should be continuous functions of depth.


Turning to the problem of heat conduction within the two-layered tissue model, the time dependent equation of heat conduction in the k-th layer was:




















t




T


(

z
,
t

)



=



α
k





2


dz
2




T


(

z
,
t

)



+


Q
k



(

z
,
t

)




,




(
2
)








yielding the following steady-state equation:












α
k





2




z
2





T


(
z
)



=

-


Q
k



(
z
)




,




(
3
)








where αk was the thermal diffusivity of the k-th layer (k=1,2). The heat source term Qk in these equations describes the generation of heat due to light absorption in the tissue. In the steady-state case, the source term is:












Q
k



(
z
)


=



μ
ak



ρ
k

·

c
k



·


ψ
k



(
z
)




,




(
4
)








where μak, ρk and ck are the coefficient of absorption, density, and specific heat of the k-th layer, respectively.


Boundary conditions were assumed to be T(0)=Ts,T(h)=Th. The solution of Equation (3) was then found to be:












T
2



(
z
)


=


T
h

+

B
·

(

h
-
z

)


-


1

α
2


·



z
h






z







hd

z








z





Q


(

z


)









,







T
1



(
z
)


=


T
s

+

A
·
z

-


1

α
1


·



0
z






z







0

z








z





Q


(

z


)









,




(
5
)








where parameters A and B have to be found from the interface conditions. For the case of perfect thermal contact:












T
1



(

h
d

)


=


T
2



(

h
d

)



,







k
1











z





T
1



(

h
d

)



=


k
2






z





T
2



(

h
d

)




,




(
6
)








where and k1 and k2 are the thermal conductivities of dermis and fat, respectively.


The analytic expression for the temperature, T(z), was then obtained by substituting Equation (3) into Equations (4) and (5).


A simpler expression for the temperature distribution was obtained for a homogenous medium with no layered structure. In this case, the radiance distribution took the following general form:

ψ(z)=F0τcol[exp(−μtz)+φd(z)],  (7)

where the first term was the collimated radiance and the second one was the diffuse radiance given by:

φd(z)=V2·exp(−κ·z)−V1·exp(−μtz).  (8)


The temperature distribution was:











T


(
z
)


=


T
s

+


(


T
h

-

T
s


)

·

z
h


+


F
0




V
0

α



{




1
-

V
1



μ
t
2


·

[

1
-




-

μ
t


·
z


-


(

1
-




-

μ
t


-
z



)

·

z
h



]


+



V
2


κ
2


·

[

1
-




-
κ

·
h


-


(

1
-




-
κ

·
h



)

·

z
h



]



}









with











V
0

=


μ
a

·


τ
sp

/


(

ρ





c

)

.








(
9
)







Differentiating Equation (9) with respect to z yields the following implicit expression for the depth zmax, the localized tissue depth at which maximum temperature occurs:











T
h

-

T
s


=




F
0

·

V
0


α

·

[




1
-

V
1



μ
t
2


·

(

1
-




-

μ
t


·
h


-


μ
t

·
h
·




-

μ
t


·

z
max





)


+



V
2


κ
2


·

(

1
-




-
κ

·
h


-

k
·
h
·




-
κ







z
max





)



]






(
10
)








Tmax=Th−Ts is maximum temperature rise in the tissue at the depth zmax.


Equation (10) was solved numerically. To get an approximate analytic expression, the inequality μt>>κ was used, which is typically valid within the therapeutic window. Then, dropping the exponential terms with μt, and solving the simplified equation with respect to zmax yielded the following










z
max

=


-

1
κ


·


ln


[



κ
·

(

1
-

V
1


)




V
2

·
h
·

μ
t
2



+


1
-

exp


(


-
κ






h

)




κ





h


-


ακ


F
0



V
0



V
2


h


·

(


T
h

-

T
s


)



]


.






(
11
)








Maximum temperature can be calculated from (9) as Tmax=T(zmax)


It can be seen from these results that an increase in F0 caused the temperature maximum to move upwards, provided the input flux is sufficiently small. At larger value of F0, the maximum ceased to move while proceeding to grow in amplitude. The treatment time should be long enough to remove heat from the layer 0<z<zmax. This time tmin was given by the formula:










t
min

=



(

6
÷
60

)

·

z
max
3





α
1

·

z
1


+


α
2

·

z
2








(
12
)








where z1 is the depth into dermis and z2 is depth into subcutaneous fat, and z1+z2=z is depth of treatment. The numerator constant (6÷60) varies within the given range depending on how close the desired temperature is to Tmax, being 6 for Tzmax=90% Tmax and 60 for Tzmax=99% Tmax. The treatment time must be longer than tmin. FIG. 11 shows a typical temperature distribution in the body. FIG. 13 and Table 2 show minimum treatment time as a function of depth of treatment z.


Equations (10), (11), and (12) describe a set of heating and cooling parameters that allow control of both the value and location of the internal temperature maximum. FIG. 11 shows a graph generated using these equations that shows that a broad spectral source, having a proper set of filters, combined with surface cooling, allows the temperature within the adipose layer of tissue to be elevated to a maximum, while maintaining acceptable temperatures surrounding tissue and in particular, in tissue above the treatment region through which the radiation passes.


Thus, this example illustrates theoretical calculations corresponding to one embodiment of the invention.


EXAMPLE 2

The following prophetic example illustrates treatment parameters for different body layers that may be used in one embodiment of the invention, as applied to human skin.


Based on the calculation illustrated in Example 1, treatment parameters for different layers of the body that may be used in one embodiment of the invention can be determined. These calculations are summarized in Table 1. The body layers model includes the reticular dermis, dermis subcutaneous fat junction, and subcutaneous fat layer.


Using a broad-spectrum lamp in this embodiment of the invention, the treatment parameters include a surface cooling mechanism able to maintain a surface cooling temperature of between 0° C. and 32° C.; a broad-spectrum lamp, where the color temperature of the lamp is between 300 K and 3000 K, with filtering of more than 50% of the light having wavelengths of less than 800 nm and greater that 1800 nm, preferably 900 to 1400 nm, and most preferably 1100 to 1250 nm. Depending on depth, the treatment being performed and other factors, the power may vary from approximately 0.2 to 50 W/cm2, and more preferably from approximately 0.5 to 20 W/cm2, with a treatment time of between 2 sec for a 1 mm depth and 7300 sec for a 50 mm depth When operating in sliding mode, treatment power and duration increase.


Thus, this prophetic example illustrates exemplary treatment parameters that may be used to heat different layers of the body, in one embodiment of the invention.









TABLE 1





Typical parameters of treatment:

















Treatment parameters



with precooling



preferable











Depth of

wavelength range












peak
Wavelength range, μm
Cooling















temperature,


Most
temperature
Precooling


Organ
mm
Maximum
Preferable
for preferable
° C.
time, s





Reticular
1-3
0.6-1.85
 0.8-1.4 &
 1.2-1.3 &
5
1-30


dermis


 1.5-1.8
 1.6-1.8


Dermis
2-5
0.6-1.35 &
 1.1-1.25 &
1.15-1.23 &
5
1-30


subcutaneous

1.6-1.8
1.65-1.8
 1.7-1.75


fat junction


Subcutaneous
 5-10
0.8-1.4 &
 1.1-1.3 &
1.15-1.23
5
30-110


fat

1.6-1.7
1.65-1.8



10-20
0.8-1.3
 1.1-1.25
1.15-1.23

110-450 



20-50
0.8-1.3
1.05-1.25
1.05-1.15

450-2800














Treatment parameters



Treatment parameters
without precooling for



with precooling
preferable wavelength range












for preferable

Minimum




wavelength range
Cooling
time of
Power













Time of
Fluence
temperature,
treatment,
density,















Organ
treatment, s
J/cm2
W/cm2
° C.
s
W/cm2



















Reticular
2-40
 10-200
  5-30
5
2-65
2.5-50



dermis



Dermis
10-40 
150-200
  5-15
5
2-65
2.5-50



subcutaneous



fat junction



Subcutaneous
40-300
200-500
1.7-5
5
65-270
0.5-20



fat
300-800 
 500-1000
1.2-5
5
270-1100
0.5-10




800-1200
1000-1200
  1-1.2
5
1100-7300 
0.2-5 

















TABLE 2







Minimum treatment time without precooling










Depth, mm
Treatment time, sec














1
2



2
10



3
20



4
40



5
65



6
95



7
130



8
170



9
220



10
275



12
400



14
550



16
720



18
915



20
1100



25
1800



30
2600



35
3500



40
4600



45
5900



50
7300










EXAMPLE 3

In this example, a device 100 of this invention substantially as shown in FIG. 2 was used to heat subcutaneous fat in the stomach region of a volunteer. Light from a halogen lamp 9 was filtered with a combination of a short cut or high pass filter 8 with an 800 nm cut-off and a 3 mm thick water layer 41. The temperature of water 41 was 12° C., while the temperature of a sapphire plate 8 and of the skin interface was 18° C. Power density was 4 W/cm2 and the treatment time was 300 sec. After heating the subcutaneous fat layer for 300 sec., the device was removed, and two thermocouples were immediately implanted 1 mm and 8 mm below the skin surface under the heated region to determine the final, steady-state temperatures and to monitor the temperature relaxation profiles in the dermis and fat layer respectively. Temperature data recorded by the two thermocouples are shown in FIG. 12. The initial temperature of the subcutaneous fat layer at a depth of 8 mm was found to be approximately 45° C., while the temperature of the dermis, 1 mm below the surface of the skin, was found to be about 40° C. and the temperature at the epidermis was 24° C. Over the course of the next several minutes, the temperatures of the dermis and the subcutaneous fat layer decreased towards basal levels of 37° C. for the subcutaneous fat layer and approximately 32° C. for the dermis.


The same device 100 was used to perform the same test on a 25 mm bulk of pig skin and subcutaneous fat which was placed on a thermally stable plate with a temperature of 37° C. The power density for this test was 10 W/cm2 and cooling water having a temperature of 4° C. was used. After a treatment time of 300 sec., peak temperature of 53° C. was found at a depth 14 mm into the fat. The temperature at the epidermis at this time was 38° C. After about 6 weeks, this exposure setting induced reduction of subcutaneous fat without evidence for epidermal damage. A partial replacement of fatty tissue by connective collagen tissue was observed. A reduction of hair growth was also observed several weeks after this and similar exposure settings, even if a lower temperature rise was obtained and only a single treatment was performed. This clearly emphasized the possibility of using this method to manage unwanted hair growth. Highly proliferating cells like sebocytes within the sebaceous glands or hair matrix cells within the hair follicle are particularly sensitive to heating which can be used to achieve selective effects on these structures even by unselective heating of the depth were these structures are located. Hair matrix cells are also surrounded by fatty cells and the sebaceous glands are generating lipids. The decreased heat capacity for lipids provides additional selective effects. This can also be specifically useful for the treatment of non pigmented hairs that are usually not affected by standard light assisted methods for photoepilation based on selective photothermolysis. Hair growth management may include permanent or temporary hair removal or merely controlling/slowing hair growth rate.


These examples thus illustrates how a device of the invention may be used to heat a subdermal layer of tissue to a temperature significantly higher than normal body temperature and the temperature of surrounding tissue, including tissue between the skin surface and the treatment region.


While several embodiments of the invention have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and structures for performing the functions and/or obtaining the results and/or advantages described herein, and each of such variations or modifications is deemed to be within the scope of the present invention. More generally, those skilled in the art would readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that actual parameters, dimensions, materials, and configurations will depend upon specific applications for which the teachings of the present invention are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, the invention may be practiced otherwise than as specifically described. The present invention is directed to each individual feature, system, material and/or method described herein. In addition, any combination of two or more such features, systems, materials and/or methods, if such features, systems, materials and/or methods are not mutually inconsistent, is included within the scope of the present invention. In the claims, all transitional phrases or phrases of inclusion, such as “comprising,” “including,” “carrying,” “having,” “containing,” and the like are to be understood to be open-ended, i.e. to mean “including but not limited to.” Only the transitional phrases or phrases of inclusion “consisting of” and “consisting essentially of” are to be interpreted as closed or semi-closed phrases, respectively.

Claims
  • 1. Apparatus for treating at least a selected region at depth of a patient while protecting tissue above the selected region, comprising: an optical radiation source for delivering infrared optical radiation at a power density of between about 0.2 W/cm2 and about 50 W/cm2 to the patient's skin, said power density varying at least in part as a function of the depth of said selected region;a water filter to at least attenuate wavelengths from said optical radiation source which are selectively absorbed by water; anda cooling mechanism configured to cool tissue.
  • 2. Apparatus as claimed in claim 1 wherein said water filter includes chilled water flowing between said optical radiation source and the patient's body, said flowing chilled water also functioning as part of said cooling mechanism.
  • 3. Apparatus as claimed in claim 1 wherein said optical radiation source provides radiation at least primarily at one or more wavelengths between about 800 nm and about 2300 nm.
  • 4. Apparatus as claimed in claim 3 wherein said source provides radiation at least primarily at one or more wavelengths between about 800 nm and about 1850 nm.
  • 5. Apparatus as claimed in claim 4 wherein said source provides radiation at least primarily at one or more wavelengths between about 800 nm and about 1350 nm.
  • 6. Apparatus as claimed in claim 4 wherein said source provides radiation at least primarily at one or more wavelengths between about 1050 nm and about 1250 nm.
  • 7. Apparatus as claimed in claim 1 wherein said source includes optics for shaping radiation to be delivered to said selected region.
  • 8. Apparatus as claimed in claim 1 wherein said optical radiation source and said cooling mechanism are concurrently operated for a period of at least two seconds.
  • 9. Apparatus as claimed in claim 8 wherein said optical radiation source and said cooling mechanism are concurrently operated for a period of at least five seconds.
  • 10. Apparatus as claimed in claim 8 including a precooling mechanism which cools tissue above said selected region prior to the concurrent operation of said optical radiation source and said cooling mechanism.
  • 11. Apparatus as claimed in claim 10 wherein said cooling mechanism and said precooling mechanism are the same mechanism.
  • 12. Apparatus as claimed in claim 10 wherein said optical radiation power and said period of concurrent operation are based at least in part on said precooling mechanism.
  • 13. Apparatus as claimed in claim 1 wherein said optical radiation source and said cooling mechanism are concurrently operated for a period of between about two seconds and about two hours.
  • 14. Apparatus as claimed in claim 1 wherein said source includes a broadband optical radiation source, and a filter through which radiation from said broadband source is passed, at least 50% of the filtered light having wavelengths between 900 nm and 1400 nm such that said apparatus is an apparatus for fat reduction, said radiation heating subdermal fat tissue.
  • 15. Apparatus as claimed in claim 1 including a stimulation mechanism for stimulating tissue in said selected region.
  • 16. Apparatus as claimed in claim 15 wherein said stimulation mechanism comprises at least one of a vibrator, a massager, a skin tensioning stimulator, acoustic stimulator, and an electrical stimulator.
  • 17. Apparatus as claimed in claim 1 wherein said selected region contains at least one hair bulb, and wherein parameters for said apparatus, including said optical radiation source, are selected to slowly damage said bulb.
  • 18. Apparatus for treating at least a selected region at depth of a patient while protecting tissue above the selected region, comprising: an optical radiation source for delivering optical radiation at a power density of between about 0.2 W/cm2 and about 50 W/cm2 to the patient's skin, said power density varying at least in part as a function of the depth of said selected region;a water filter to at least attenuate wavelengths from said optical radiation source which are selectively absorbed by water;a cooling mechanism configured to cool tissue; anda mechanism for removing heat from said water filter.
  • 19. A method for treating at least a selected region at depth of a patient's body while protecting tissue above the selected region, comprising: (a) selectively delivering optical radiation generated by a narrow spectral source at a power density between approximately 0.2 W/cm2 and 50 W/cm2 to the patient's body above said selected region, said power density varying at least in part as a function of the depth of said selected region, said optical radiation being applied to said selected region for at least approximately 2 seconds; and(b) concurrently cooling patient tissue above said selected region to a temperature below that of the selected region.
  • 20. A method as claimed in claim 19 wherein said power density is between about 0.5 W/cm2 and about 20 W/cm2.
  • 21. A method as claimed in claim 19 wherein step (a) includes filtering said optical radiation before delivering it to said patient's body.
  • 22. A method as claimed in claim 19 wherein said method is a method for performing therapy on at least one of subdermal muscle, ligament and bone, said radiation causing heating of such muscle/ligament/bone and of tissue in the area thereof to at least increase blood flow in such area.
  • 23. A method as claimed in claim 19 wherein said method is a method for treating a selected unwanted growth, said radiation heating said growth sufficiently to cause the destruction thereof.
  • 24. The method of claim 19, wherein the electromagnetic energy is at least primarily at one or more wavelengths between about 600 nm and about 1850 nm.
  • 25. The method of claim 24, wherein the electromagnetic energy is at least primarily at one or more wavelengths between about 800 nm and about 1350 nm.
  • 26. The method of claim 24 wherein the electromagnetic energy is at least primarily at one or more wavelengths between about 1050 nm and about 1250 nm.
  • 27. The method of claim 19 wherein step (a) and step (b) are performed concurrently for a period of at least two seconds.
  • 28. The method of claim 27 wherein step (a) and step (b) are performed concurrently for a period of at least five seconds.
  • 29. The method of claim 19 wherein step (a) and step (b) are performed concurrently for a period of between about two seconds and about two hours.
  • 30. The method of claim 19 including the step of precooling tissue above said selected region.
  • 31. The method of claim 30 wherein said optical radiation power and a period of said concurrent operation are based at least in part on said precooling step.
  • 32. The method of claim 19 wherein said selected region is heated during step (a).
  • 33. The method of claim 19 including the step of stimulating tissue in said selected region.
  • 34. The method of claim 33 wherein said step of providing stimulation provides at least one of vibrating stimulation, massaging stimulation, skin tensioning, acoustic stimulation and electrical stimulation.
  • 35. The method of claim 19 wherein said selected region contains at least one hair bulb, and wherein parameters for said method, including said radiation, are selected to slowly damage said bulb.
  • 36. A method for treating at least a selected region at depth of a patient's body while protecting tissue above the selected region, comprising: (a) selectively delivering radiation to the patient's body above said selected region to heat the region;(b) concurrently cooling patient tissue above said selected region to a temperature below that of the selected region; and(c) applying at least one of vibrating, massaging, skin tensioning, acoustic and electrical stimulation to said region.
  • 37. The method of claim 19, further comprising: (c) applying at least one of vibrating, massaging, skin tensioning, acoustic and electrical stimulation to said region.
  • 38. The method of claim 19, wherein said method is a method for performing at least one of wrinkle removal, pain treatment, and cellulite treatment.
  • 39. The method of claim 19, wherein said narrow spectral optical radiation source is a monochromatic source.
  • 40. The method of claim 19, wherein said narrow spectral optical radiation source is a laser.
  • 41. The method of claim 40, wherein said laser is a fiber laser or a diode laser.
  • 42. The method of claim 19, wherein said narrow spectral optical radiation source is an LED.
  • 43. A method for treating at least a selected region at depth of a patient's body while protecting tissue above the selected region, comprising: (a) selectively delivering optical radiation at a power density between about 0.5 W/cm2 and about 5 W/cm2 to the selected region, said optical radiation being applied to said selected region for at least approximately 2 seconds; and(b) concurrently cooling patient tissue above said selected region to a temperature below that of the selected region.
  • 44. Apparatus for treating at least a selected region at depth of a patient while protecting tissue above the selected region, comprising: a narrow spectral optical radiation source for delivering infrared radiation at a power density of between approximately 0.2 W/cm2 and 50 W/cm2 to the patient's skin for a duration between two seconds and two hours, both said power density and said duration increasing with increased depth for said selected region; anda cooling mechanism for cooling tissue above said selected region to a temperature below that of said selected region.
  • 45. The apparatus of claim 44, wherein said optical radiation source provides radiation at least primarily at one or more wavelengths between about 800 nm and about 2300 nm.
  • 46. The apparatus of claim 44, wherein said optical radiation source provides radiation at least primarily at one or more wavelengths between about 800 nm and about 1850 nm.
  • 47. Apparatus for treating at least a selected region at depth of a patient while protecting tissue above the selected region, comprising: a narrow spectral optical radiation source for delivering radiation of a wavelength between 600 nm and 1850 nm and at a power density of between approximately 0.2 W/cm2 and 5 W/cm2 to the patient's skin, the wavelength and the power density both varying as a function of the depth of the selected region; anda cooling mechanism for cooling tissue above said selected region to a temperature below that of said selected region.
  • 48. Apparatus for treating at least a selected region at depth of a patient while protecting tissue above the selected region, comprising: a narrow spectral optical radiation source for delivering radiation of a wavelength between about 600 nm and about 1850 nm, at a power density of between approximately 0.2 W/cm2 and 50 W/cm2 to the patient's skin for a duration between about two seconds and two hours, the wavelength, duration and power density all varying as a function of the depth of the selected region; anda cooling mechanism for cooling tissue above said selected region to a temperature below that of said selected region.
  • 49. The apparatus of claim 48, wherein said narrow spectral optical radiation source is a monochromatic source.
  • 50. The apparatus of claim 48, wherein said narrow spectral optical radiation source is a laser.
  • 51. The apparatus of claim 50, wherein said laser is a fiber laser or a diode laser.
  • 52. The apparatus of claim 48, wherein said narrow spectral optical radiation source is an LED.
  • 53. A method for treating subdermal fat at depth of a patient's body, comprising: (a) selectively delivering radiation at a power density between approximately 0.2 W/cm2 and 50 W/cm2 to a selected region of subdermal fat of the patient's body for a duration of about two seconds to about two hours, both said power density and said duration varying with the depth of said selected region; and(b) concurrently cooling patient tissue above said selected region to a temperature below that of the selected region.
  • 54. The method of claim 53, wherein said radiation has a wavelength selected from the group of about 925 nm, about 1206 nm, about 1730 nm and about 2300 nm.
  • 55. A method for treating at least a selected region at depth of a patient's body while protecting tissue above the selected region, comprising: (a) selectively delivering radiation of a wavelength between about 600 nm and about 1850 nm and at a power density between approximately 0.2 W/cm2 and 5 W/cm2 to the patient's body above said selected region, both said power density and wavelength varying as a function of the depth of said selected region; and(b) concurrently cooling patient tissue above said selected region to a temperature below that of the selected region.
  • 56. A method as claimed in claim 36 wherein said selected region contains subdermal fat; and wherein said radiation at least includes at least one wavelength selectively absorbed by fat.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 10/465,137 filed Jun. 19, 2003, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/389,871, filed Jun. 19, 2002, entitled “Method and Apparatus for Subdermal Heating,” by G. Altshuler, et al., incorporated herein by reference in their entirety.

US Referenced Citations (1244)
Number Name Date Kind
853033 Roberts May 1907 A
1590283 Catlin Jun 1926 A
1676183 Garfunkle Jul 1928 A
1706161 Hollnagel Mar 1929 A
2068721 Wappler et al. Jan 1937 A
2472385 Rollman Jun 1949 A
2669771 Burge et al. Feb 1954 A
3243650 Hawkins et al. Mar 1966 A
3261978 Brenman Jul 1966 A
3284665 Goncz Nov 1966 A
3327712 Kaufman et al. Jun 1967 A
3465203 Michaels et al. Sep 1969 A
3486070 Engel Dec 1969 A
3524144 Buser et al. Aug 1970 A
3527932 Thomas Sep 1970 A
3538919 Meyer Nov 1970 A
3597652 Gates, Jr. Aug 1971 A
3622743 Muncheryan Nov 1971 A
3651425 McKnight Mar 1972 A
3653778 Freiling Apr 1972 A
3667454 Prince Jun 1972 A
3693623 Harte et al. Sep 1972 A
3699967 Anderson Oct 1972 A
3725733 Mack et al. Apr 1973 A
3766393 Herzog et al. Oct 1973 A
3766488 Kohn Oct 1973 A
3769963 Goldman et al. Nov 1973 A
3793723 Kuris et al. Feb 1974 A
3794028 Mueller et al. Feb 1974 A
3815046 Johnson et al. Jun 1974 A
3818373 Chun et al. Jun 1974 A
3818914 Bender Jun 1974 A
3821510 Muncheryan Jun 1974 A
3834391 Block Sep 1974 A
3843865 Nath Oct 1974 A
3846811 Nakamura et al. Nov 1974 A
3857015 Clark et al. Dec 1974 A
3858577 Bass et al. Jan 1975 A
3885569 Judson May 1975 A
3890537 Park et al. Jun 1975 A
3900034 Katz Aug 1975 A
3909649 Arsena Sep 1975 A
3914709 Pike et al. Oct 1975 A
3939560 Lyall Feb 1976 A
3977083 Leslie et al. Aug 1976 A
3980861 Fukunaga Sep 1976 A
4019156 Fountain et al. Apr 1977 A
4037136 Hoene Jul 1977 A
4038984 Sittner Aug 1977 A
4047106 Robinson Sep 1977 A
4065370 Noble et al. Dec 1977 A
4122853 Smith Oct 1978 A
4133503 Bliss Jan 1979 A
4139342 Sheldrake et al. Feb 1979 A
4154240 Ikuno et al. May 1979 A
4176324 Aldag et al. Nov 1979 A
4188927 Harris Feb 1980 A
4213462 Sato Jul 1980 A
4228800 Degler, Jr. et al. Oct 1980 A
4233493 Nath Nov 1980 A
4254333 Bergstrom Mar 1981 A
4269067 Tynan et al. May 1981 A
4273109 Enderby Jun 1981 A
4275335 Ishida Jun 1981 A
4291281 Pinard et al. Sep 1981 A
4292601 Aldag et al. Sep 1981 A
4293827 McAllister et al. Oct 1981 A
4298005 Mutzhas Nov 1981 A
4302730 Jernigan Nov 1981 A
4313431 Frank Feb 1982 A
4316467 Muckerheide Feb 1982 A
4333197 Kuris Jun 1982 A
4335726 Kolstedt Jun 1982 A
4336809 Clark Jun 1982 A
4364015 Drake et al. Dec 1982 A
4375684 Everett Mar 1983 A
4388924 Weissman et al. Jun 1983 A
4409479 Sprague et al. Oct 1983 A
4435808 Javan Mar 1984 A
4445217 Acharekar et al. Apr 1984 A
4452081 Seppi Jun 1984 A
4456872 Froeschle Jun 1984 A
4461294 Baron Jul 1984 A
4488104 Suzuki Dec 1984 A
4489415 Jones et al. Dec 1984 A
4503854 Jako Mar 1985 A
4504727 Melcher et al. Mar 1985 A
4512197 von Gutfeld et al. Apr 1985 A
4524289 Hammond et al. Jun 1985 A
4539987 Nath et al. Sep 1985 A
4553546 Javelle Nov 1985 A
4555786 Byer Nov 1985 A
4559943 Bowers Dec 1985 A
4561440 Kubo et al. Dec 1985 A
4566271 French et al. Jan 1986 A
4566438 Liese et al. Jan 1986 A
4569345 Manes Feb 1986 A
4576177 Webster, Jr. Mar 1986 A
4587968 Price May 1986 A
4591762 Nakamura May 1986 A
4592353 Daikuzono Jun 1986 A
4601037 McDonald Jul 1986 A
4601753 Soileau et al. Jul 1986 A
4608978 Rohr Sep 1986 A
4608979 Breidenthal et al. Sep 1986 A
4617926 Sutton Oct 1986 A
4623929 Johnson et al. Nov 1986 A
4629884 Bergstrom Dec 1986 A
4638800 Michel Jan 1987 A
4653495 Nanaumi Mar 1987 A
4656641 Scifres et al. Apr 1987 A
4662368 Hussein et al. May 1987 A
4677347 Nakamura et al. Jun 1987 A
4686986 Fenyo et al. Aug 1987 A
4693244 Daikuzono Sep 1987 A
4693556 McCaughan, Jr. Sep 1987 A
4695697 Kosa Sep 1987 A
4710677 Halberstadt et al. Dec 1987 A
4718416 Nanaumi Jan 1988 A
4724835 Liss et al. Feb 1988 A
4733660 Itzkan Mar 1988 A
4735201 O'Reilly Apr 1988 A
4736743 Daikuzono Apr 1988 A
4736745 Gluckman Apr 1988 A
4740047 Abe et al. Apr 1988 A
4745909 Pelton et al. May 1988 A
4747660 Nishioka et al. May 1988 A
4749913 Stuermer et al. Jun 1988 A
4759349 Betz et al. Jul 1988 A
4773413 Hussein et al. Sep 1988 A
4775361 Jacques et al. Oct 1988 A
4779173 Carr et al. Oct 1988 A
4784135 Blum et al. Nov 1988 A
4799479 Spears Jan 1989 A
4813412 Yamazaki et al. Mar 1989 A
4813762 Leger et al. Mar 1989 A
4819669 Politzer Apr 1989 A
4826431 Fujimura et al. May 1989 A
4829262 Furumoto May 1989 A
4832024 Boussignac et al. May 1989 A
4840174 Gluckman Jun 1989 A
4840563 Altendorf Jun 1989 A
4845608 Gdula Jul 1989 A
4848339 Rink et al. Jul 1989 A
4852107 Hamal et al. Jul 1989 A
4852549 Mori et al. Aug 1989 A
4860172 Schlager et al. Aug 1989 A
4860303 Russell Aug 1989 A
4860743 Abela Aug 1989 A
4860744 Johnson et al. Aug 1989 A
4862886 Clarke et al. Sep 1989 A
4862888 Yessik Sep 1989 A
4862903 Campbell Sep 1989 A
4871479 Bachelard et al. Oct 1989 A
4878224 Kuder Oct 1989 A
4884560 Kuracina Dec 1989 A
4887600 Watson et al. Dec 1989 A
4889525 Yuhas et al. Dec 1989 A
4890898 Bentley et al. Jan 1990 A
4891817 Duarte Jan 1990 A
4896329 Knaak Jan 1990 A
4898438 Mori Feb 1990 A
4898439 Mori Feb 1990 A
4901323 Hawkins et al. Feb 1990 A
4905690 Ohshiro et al. Mar 1990 A
4910438 Farnsworth Mar 1990 A
4913142 Kittrell et al. Apr 1990 A
4914298 Quad et al. Apr 1990 A
4917084 Sinofsky Apr 1990 A
4926227 Jensen May 1990 A
4928038 Nerone May 1990 A
4930504 Diamantopoulos et al. Jun 1990 A
4931053 L'Esperance Jun 1990 A
4932954 Wondrazek et al. Jun 1990 A
4945239 Wist et al. Jul 1990 A
4950266 Sinofsky Aug 1990 A
4955882 Hakky Sep 1990 A
4968314 Michaels Nov 1990 A
4972427 Streifer et al. Nov 1990 A
4973848 Kolobanov et al. Nov 1990 A
4976308 Faghri Dec 1990 A
4976709 Sand Dec 1990 A
4977571 Furumoto et al. Dec 1990 A
4978186 Mori Dec 1990 A
4979180 Muncheryan Dec 1990 A
4992256 Skaggs et al. Feb 1991 A
4994060 Rink et al. Feb 1991 A
5000752 Hoskin et al. Mar 1991 A
5006293 Hartman et al. Apr 1991 A
5009658 Damgaard-Iversen Apr 1991 A
5011483 Sleister Apr 1991 A
5027359 Leger et al. Jun 1991 A
5030090 Maeda et al. Jul 1991 A
5032178 Cornell Jul 1991 A
5037421 Boutacoff et al. Aug 1991 A
5041109 Abela Aug 1991 A
5046494 Searfoss et al. Sep 1991 A
5050597 Daikuzono Sep 1991 A
5056515 Abel Oct 1991 A
5057099 Rink Oct 1991 A
5057104 Chess Oct 1991 A
5059192 Zaias Oct 1991 A
5061266 Hakky Oct 1991 A
5065515 Iderosa Nov 1991 A
5066292 Müller et al. Nov 1991 A
5066293 Furumoto Nov 1991 A
5071416 Heller et al. Dec 1991 A
5071417 Sinofsky Dec 1991 A
5080660 Buelna Jan 1992 A
5090019 Scheps Feb 1992 A
5092865 Rink Mar 1992 A
5102410 Dressel Apr 1992 A
5108388 Trokel Apr 1992 A
5109387 Garden et al. Apr 1992 A
5112328 Taboada et al. May 1992 A
5127395 Bontemps Jul 1992 A
5129896 Hasson Jul 1992 A
5129897 Daikuzono Jul 1992 A
5132980 Connors et al. Jul 1992 A
5133102 Sakuma et al. Jul 1992 A
5137530 Sand Aug 1992 A
5140608 Karpol et al. Aug 1992 A
5140984 Dew et al. Aug 1992 A
5147353 Everett Sep 1992 A
5147356 Bhatta Sep 1992 A
5151097 Daikuzono Sep 1992 A
5159601 Huber Oct 1992 A
5160194 Feldman Nov 1992 A
5163935 Black et al. Nov 1992 A
5171564 Nathoo et al. Dec 1992 A
5178617 Kuizenga et al. Jan 1993 A
5180378 Kung et al. Jan 1993 A
5182557 Lang Jan 1993 A
5182857 Simon Feb 1993 A
5190541 Abele et al. Mar 1993 A
5191883 Lennox et al. Mar 1993 A
5192278 Hayes et al. Mar 1993 A
5193526 Daikuzono Mar 1993 A
5196004 Sinofsky Mar 1993 A
5197470 Helfer et al. Mar 1993 A
5201731 Hakky Apr 1993 A
5207671 Franken et al. May 1993 A
5207672 Roth et al. May 1993 A
5207673 Ebling et al. May 1993 A
5209748 Daikuzono May 1993 A
5213092 Uram May 1993 A
5217455 Tan Jun 1993 A
5219347 Negus et al. Jun 1993 A
5222907 Katabuchi et al. Jun 1993 A
5222953 Dowlatshaki Jun 1993 A
5225926 Cuomo et al. Jul 1993 A
5226907 Tankovich Jul 1993 A
5242437 Everett et al. Sep 1993 A
5242438 Saadatmanesh Sep 1993 A
5246436 Rowe Sep 1993 A
5249192 Kuizenga et al. Sep 1993 A
5254114 Reed, Jr. et al. Oct 1993 A
5255277 Carvalho Oct 1993 A
5257970 Dougherty Nov 1993 A
5257991 Fletcher et al. Nov 1993 A
5261904 Baker et al. Nov 1993 A
5267399 Johnston Dec 1993 A
5267995 Doiron et al. Dec 1993 A
5267998 Hagen Dec 1993 A
5269777 Doiron et al. Dec 1993 A
5269780 Roos Dec 1993 A
5281211 Parel et al. Jan 1994 A
5281216 Klicek Jan 1994 A
5282797 Chess Feb 1994 A
5284154 Raymond et al. Feb 1994 A
5287372 Ortiz Feb 1994 A
5287380 Hsia Feb 1994 A
5290273 Tan Mar 1994 A
5290274 Levy et al. Mar 1994 A
5292320 Brown et al. Mar 1994 A
5293880 Levitt Mar 1994 A
5300063 Tano et al. Apr 1994 A
5300065 Anderson Apr 1994 A
5300097 Lerner et al. Apr 1994 A
5303585 Lichte Apr 1994 A
5304167 Freiberg Apr 1994 A
5304170 Green Apr 1994 A
5304173 Kittrell et al. Apr 1994 A
5306143 Levy Apr 1994 A
5306274 Long Apr 1994 A
5307369 Kimberlin Apr 1994 A
5308311 Eggers et al. May 1994 A
5312395 Tan et al. May 1994 A
5312396 Feld et al. May 1994 A
5320618 Gustafsson Jun 1994 A
5320620 Long et al. Jun 1994 A
5330470 Hagen Jul 1994 A
5331649 Dacquay et al. Jul 1994 A
5334191 Poppas et al. Aug 1994 A
5334193 Nardella Aug 1994 A
5336217 Buys et al. Aug 1994 A
5336221 Anderson Aug 1994 A
5342358 Daikuzono et al. Aug 1994 A
5344418 Ghaffari Sep 1994 A
5344434 Talmore Sep 1994 A
5346488 Prince et al. Sep 1994 A
5348551 Spears et al. Sep 1994 A
5349590 Amirkhanian et al. Sep 1994 A
5350376 Brown Sep 1994 A
5353020 Schurmann Oct 1994 A
5353790 Jacques et al. Oct 1994 A
5354294 Chou Oct 1994 A
5356081 Sellar Oct 1994 A
5358503 Bertwell et al. Oct 1994 A
5360426 Muller et al. Nov 1994 A
5366456 Rink et al. Nov 1994 A
5368031 Cline et al. Nov 1994 A
5368038 Fraden Nov 1994 A
5369831 Bock Dec 1994 A
5370642 Keller Dec 1994 A
5370649 Gardetto et al. Dec 1994 A
5380317 Everett et al. Jan 1995 A
5383876 Nardella Jan 1995 A
5386427 Zayhowski Jan 1995 A
5387211 Saadatmanesh Feb 1995 A
5395356 King et al. Mar 1995 A
5403306 Edwards et al. Apr 1995 A
5405368 Eckhouse Apr 1995 A
5409446 Rattner Apr 1995 A
5409479 Dew et al. Apr 1995 A
5409481 Poppas et al. Apr 1995 A
5415654 Daikuzono May 1995 A
5421337 Richards-Kortum Jun 1995 A
5421339 Ramanujam et al. Jun 1995 A
5422112 Williams Jun 1995 A
5423800 Ren et al. Jun 1995 A
5423803 Tankovich et al. Jun 1995 A
5423805 Brucker et al. Jun 1995 A
5425728 Tankovich Jun 1995 A
5425735 Rosen et al. Jun 1995 A
5425754 Braun et al. Jun 1995 A
5439954 Bush Aug 1995 A
5441499 Fritzsch Aug 1995 A
5445608 Chen et al. Aug 1995 A
5445611 Eppstein et al. Aug 1995 A
5454807 Lennox et al. Oct 1995 A
5456682 Edwards et al. Oct 1995 A
5458140 Eppstein et al. Oct 1995 A
5464436 Smith Nov 1995 A
5470331 Daikuzono Nov 1995 A
5472748 Wolfe et al. Dec 1995 A
5474549 Ortiz et al. Dec 1995 A
5484436 Eggers et al. Jan 1996 A
5486170 Winston et al. Jan 1996 A
5486172 Chess Jan 1996 A
5488626 Heller et al. Jan 1996 A
5489256 Adair Feb 1996 A
5492894 Bascom et al. Feb 1996 A
5496305 Kittrell et al. Mar 1996 A
5496307 Daikuzono Mar 1996 A
5498935 McMahan et al. Mar 1996 A
5499313 Kleinerman Mar 1996 A
5501680 Kurtz et al. Mar 1996 A
5502582 Larson et al. Mar 1996 A
5505726 Meserol Apr 1996 A
5505727 Keller Apr 1996 A
5507739 Vassiliadis et al. Apr 1996 A
5519534 Smith May 1996 A
5521367 Bard et al. May 1996 A
5522813 Trelles Jun 1996 A
5527350 Grove et al. Jun 1996 A
5527368 Supkis et al. Jun 1996 A
5530711 Scheps Jun 1996 A
5531739 Trelles Jul 1996 A
5531740 Black Jul 1996 A
5536168 Bourke et al. Jul 1996 A
5540676 Freiberg Jul 1996 A
5540678 Long et al. Jul 1996 A
5540681 Strul et al. Jul 1996 A
5541948 Krupke et al. Jul 1996 A
5546214 Black et al. Aug 1996 A
5549660 Mendes et al. Aug 1996 A
5557625 Durville Sep 1996 A
5558666 Dewey et al. Sep 1996 A
5558667 Yarborough et al. Sep 1996 A
5561881 Klinger et al. Oct 1996 A
5571098 Domankevitz et al. Nov 1996 A
5578029 Trelles et al. Nov 1996 A
5578866 DePoorter et al. Nov 1996 A
5595568 Anderson et al. Jan 1997 A
5598426 Hsia et al. Jan 1997 A
5608210 Esparza et al. Mar 1997 A
5611793 Wilson et al. Mar 1997 A
5616140 Prescott Apr 1997 A
5618284 Sand Apr 1997 A
5620478 Eckhouse Apr 1997 A
5624435 Furumoto et al. Apr 1997 A
5626631 Eckhouse May 1997 A
5628744 Coleman et al. May 1997 A
5628771 Mizukawa et al. May 1997 A
5630811 Miller May 1997 A
5632741 Zavislan et al. May 1997 A
5634711 Kennedy et al. Jun 1997 A
5647866 Zaias et al. Jul 1997 A
5649972 Hochstein Jul 1997 A
5651783 Reynard Jul 1997 A
5652481 Johnson et al. Jul 1997 A
5653706 Zavislan et al. Aug 1997 A
5655547 Karni Aug 1997 A
5657760 Ying et al. Aug 1997 A
5658148 Neuberger et al. Aug 1997 A
5658323 Miller Aug 1997 A
5660836 Knowlton Aug 1997 A
5661744 Murakami et al. Aug 1997 A
5662643 Kung et al. Sep 1997 A
5662644 Swor Sep 1997 A
5668824 Furumoto Sep 1997 A
5671315 Tabuchi et al. Sep 1997 A
5673451 Moore et al. Oct 1997 A
5679113 Caisey et al. Oct 1997 A
5683380 Eckhouse et al. Nov 1997 A
5684902 Tada Nov 1997 A
5688266 Edwards et al. Nov 1997 A
5688267 Panescu et al. Nov 1997 A
5692509 Voss et al. Dec 1997 A
5698866 Doiron et al. Dec 1997 A
5707369 Vaitekunas et al. Jan 1998 A
5707401 Talmore Jan 1998 A
5707403 Grove et al. Jan 1998 A
5713738 Yarborough Feb 1998 A
5714119 Kawagoe et al. Feb 1998 A
5720772 Eckhouse Feb 1998 A
5722397 Eppstein Mar 1998 A
5725522 Sinofsky Mar 1998 A
5728090 Martin et al. Mar 1998 A
5735844 Anderson et al. Apr 1998 A
5735884 Thompson et al. Apr 1998 A
5738678 Patel Apr 1998 A
5742392 Anderson et al. Apr 1998 A
5743901 Grove et al. Apr 1998 A
5743902 Trost Apr 1998 A
5746735 Furumoto et al. May 1998 A
5748822 Miura et al. May 1998 A
5749868 Furumoto May 1998 A
5755751 Eckhouse May 1998 A
5759162 Oppelt et al. Jun 1998 A
5759200 Azar Jun 1998 A
5760362 Eloy Jun 1998 A
5769076 Mackawa et al. Jun 1998 A
5776129 Mersch Jul 1998 A
5782249 Weber et al. Jul 1998 A
5802136 Carol Sep 1998 A
5807386 Slatkine et al. Sep 1998 A
5810801 Anderson et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5812567 Jeon et al. Sep 1998 A
5813855 Crisio, Jr. Sep 1998 A
5814008 Chen et al. Sep 1998 A
5814040 Nelson et al. Sep 1998 A
5814041 Anderson et al. Sep 1998 A
5817089 Tankovich et al. Oct 1998 A
5818580 Murnick Oct 1998 A
5820625 Izawa et al. Oct 1998 A
5820626 Baumgardner Oct 1998 A
5822034 Shimashita et al. Oct 1998 A
5824023 Anderson Oct 1998 A
5827264 Hohla Oct 1998 A
5828803 Eckhouse Oct 1998 A
5830208 Muller Nov 1998 A
5830209 Savage et al. Nov 1998 A
5835648 Narciso, Jr. et al. Nov 1998 A
5836877 Zavislan Nov 1998 A
5836999 Eckhouse et al. Nov 1998 A
5837001 Mackey Nov 1998 A
5840048 Cheng Nov 1998 A
5843072 Furumoto et al. Dec 1998 A
5849029 Eckhouse et al. Dec 1998 A
5851181 Talmor Dec 1998 A
5853407 Miller Dec 1998 A
5860967 Zavislan et al. Jan 1999 A
5868731 Budnik et al. Feb 1999 A
5868732 Waldman et al. Feb 1999 A
5871479 Furumoto et al. Feb 1999 A
5871480 Tankovich Feb 1999 A
5879159 Cipolla Mar 1999 A
5879346 Waldman et al. Mar 1999 A
5879376 Miller Mar 1999 A
5883471 Rodman et al. Mar 1999 A
5885211 Eppstein et al. Mar 1999 A
5885273 Eckhouse et al. Mar 1999 A
5885274 Fullmer et al. Mar 1999 A
5891063 Vigil Apr 1999 A
5893828 Uram Apr 1999 A
5893885 Webster, Jr. Apr 1999 A
5895350 Hori Apr 1999 A
5897549 Tankovich Apr 1999 A
5906609 Assa et al. May 1999 A
5908418 Dority et al. Jun 1999 A
5913833 Elstrom et al. Jun 1999 A
5913883 Alexander et al. Jun 1999 A
5916211 Quon et al. Jun 1999 A
5920374 Vaphiades et al. Jul 1999 A
5921926 Rolland et al. Jul 1999 A
5928222 Kleinerman Jul 1999 A
5935124 Klumb et al. Aug 1999 A
5944687 Benett et al. Aug 1999 A
5944748 Mager et al. Aug 1999 A
5948011 Knowlton Sep 1999 A
5949222 Buono Sep 1999 A
5951543 Brauer Sep 1999 A
5954710 Paolini et al. Sep 1999 A
5955490 Kennedy et al. Sep 1999 A
5957915 Trost Sep 1999 A
5964749 Eckhouse et al. Oct 1999 A
5968033 Fuller Oct 1999 A
5968034 Fullmer et al. Oct 1999 A
5971976 Wang et al. Oct 1999 A
5974059 Dawson Oct 1999 A
5974616 Dreyfus Nov 1999 A
5976123 Baumgardner et al. Nov 1999 A
5977723 Yoon Nov 1999 A
5979454 Anvari et al. Nov 1999 A
5983900 Clement et al. Nov 1999 A
5984915 Loeb et al. Nov 1999 A
6007219 O'Meara Dec 1999 A
6015404 Altshuler et al. Jan 2000 A
6022316 Eppstein et al. Feb 2000 A
6022346 Panescu et al. Feb 2000 A
6024095 Stanley, III Feb 2000 A
6026828 Altshuler Feb 2000 A
6027493 Donitzky et al. Feb 2000 A
6027495 Miller Feb 2000 A
6028694 Schmidt Feb 2000 A
6029303 Dewan Feb 2000 A
6029304 Hulke et al. Feb 2000 A
6030378 Stewart Feb 2000 A
6030399 Ignotz et al. Feb 2000 A
6032071 Binder Feb 2000 A
RE36634 Ghaffari Mar 2000 E
6033431 Segal Mar 2000 A
6036684 Tankovich et al. Mar 2000 A
6044514 Kaneda et al. Apr 2000 A
6045548 Furumoto et al. Apr 2000 A
6050990 Tankovich et al. Apr 2000 A
D424197 Sydlowski et al. May 2000 S
6056548 Neuberger et al. May 2000 A
6056738 Marchitto et al. May 2000 A
6058937 Doiron et al. May 2000 A
6059820 Baronov May 2000 A
6063108 Salansky et al. May 2000 A
6070092 Kazama et al. May 2000 A
6071239 Cribbs et al. Jun 2000 A
6074382 Asah et al. Jun 2000 A
6077294 Cho et al. Jun 2000 A
6080146 Altshuler et al. Jun 2000 A
6080147 Tobinick Jun 2000 A
6083217 Tankovich Jul 2000 A
6086363 Moran et al. Jul 2000 A
6086558 Bower et al. Jul 2000 A
6086580 Mordon et al. Jul 2000 A
6094767 Iimura Aug 2000 A
6096028 Bahmanyar et al. Aug 2000 A
6096029 O'Donnell, Jr. Aug 2000 A
6096209 O'Brien et al. Aug 2000 A
6099521 Shadduck Aug 2000 A
6101207 Ilorinne Aug 2000 A
6104959 Spertell Aug 2000 A
6106293 Wiesel Aug 2000 A
6106294 Daniel Aug 2000 A
6110195 Xie et al. Aug 2000 A
6112123 Kelleher et al. Aug 2000 A
6113559 Klopotek Sep 2000 A
6117129 Mukai Sep 2000 A
6120497 Anderson Sep 2000 A
6126655 Domankevitz et al. Oct 2000 A
6129723 Anderson et al. Oct 2000 A
6135774 Hack et al. Oct 2000 A
6142650 Brown et al. Nov 2000 A
6142939 Eppstein et al. Nov 2000 A
6149644 Xie Nov 2000 A
6149895 Kutsch Nov 2000 A
6159203 Sinofsky et al. Dec 2000 A
6159236 Biel Dec 2000 A
6162055 Montgomery et al. Dec 2000 A
6162211 Tankovich et al. Dec 2000 A
6162212 Kreindel et al. Dec 2000 A
6162215 Feng Dec 2000 A
6162218 Elbrecht et al. Dec 2000 A
6164837 Haake et al. Dec 2000 A
6171300 Adams Jan 2001 B1
6171301 Nelson Jan 2001 B1
6171302 Talpalriu et al. Jan 2001 B1
6171332 Whitehurst Jan 2001 B1
6173202 Eppstein et al. Jan 2001 B1
6174325 Eckhouse Jan 2001 B1
6176854 Cone Jan 2001 B1
6183434 Eppstein Feb 2001 B1
6183500 Kohler Feb 2001 B1
6183773 Anderson Feb 2001 B1
6187001 Azar et al. Feb 2001 B1
6187029 Shapiro et al. Feb 2001 B1
6197020 O'Donnell Mar 2001 B1
6200134 Kovac et al. Mar 2001 B1
6200309 Rice et al. Mar 2001 B1
6202242 Salmon et al. Mar 2001 B1
6203540 Weber Mar 2001 B1
6210425 Chen Apr 2001 B1
6210426 Cho et al. Apr 2001 B1
6214034 Azar Apr 2001 B1
6221068 Fried et al. Apr 2001 B1
6221095 Van Zuylen et al. Apr 2001 B1
6228074 Almeida May 2001 B1
6228075 Furumoto May 2001 B1
6229831 Nightingale et al. May 2001 B1
6230044 Afanassieva et al. May 2001
6235015 Mead, III et al. May 2001 B1
6235016 Stewart May 2001 B1
6236891 Ingel et al. May 2001 B1
6239442 Iimura et al. May 2001 B1
6240306 Rohrscheib et al. May 2001 B1
6240925 McMillan et al. Jun 2001 B1
6245093 Li et al. Jun 2001 B1
6246710 Furumoto Jun 2001 B1
6248103 Tannenbaum et al. Jun 2001 B1
6251127 Biel Jun 2001 B1
6254388 Yarborough Jul 2001 B1
6263233 Zavislan et al. Jul 2001 B1
6264649 Whitcroft et al. Jul 2001 B1
6267779 Gerdes Jul 2001 B1
6267780 Streeter Jul 2001 B1
6273883 Furumoto Aug 2001 B1
6273884 Altshuler et al. Aug 2001 B1
6273885 Koop et al. Aug 2001 B1
6280438 Eckhouse et al. Aug 2001 B1
6282442 Destefano et al. Aug 2001 B1
6283956 McDaniel Sep 2001 B1
6287549 Sumian et al. Sep 2001 B1
6290496 Azar et al. Sep 2001 B1
6290712 Nordquist et al. Sep 2001 B1
6290713 Russell Sep 2001 B1
6306130 Anderson et al. Oct 2001 B1
6306160 Nidetzky Oct 2001 B1
6315772 Marchitto et al. Nov 2001 B1
6317624 Kollias et al. Nov 2001 B1
6319274 Shadduck Nov 2001 B1
6322584 Ingle et al. Nov 2001 B2
6325769 Klopotek Dec 2001 B1
6327506 Yogo et al. Dec 2001 B1
6328733 Trost Dec 2001 B1
6331111 Cao Dec 2001 B1
6332891 Himes Dec 2001 B1
6338855 Albacarys et al. Jan 2002 B1
6340495 Sumian et al. Jan 2002 B1
6343400 Massholder et al. Feb 2002 B1
6343933 Montgomery et al. Feb 2002 B1
6350261 Domankevitz et al. Feb 2002 B1
6350276 Knowlton Feb 2002 B1
6354370 Miller et al. Mar 2002 B1
6355054 Neuberger et al. Mar 2002 B1
6358242 Cecchetti Mar 2002 B1
6358272 Wilden Mar 2002 B1
6364872 Hsia et al. Apr 2002 B1
6383176 Connors et al. May 2002 B1
6383177 Balle-Petersen et al. May 2002 B1
6387089 Kreindel et al. May 2002 B1
6387353 Jensen et al. May 2002 B1
6391022 Furumoto et al. May 2002 B1
6394949 Crowley et al. May 2002 B1
6395016 Oron et al. May 2002 B1
6398801 Clement et al. Jun 2002 B1
6400011 Miki Jun 2002 B1
6402739 Neev Jun 2002 B1
6405732 Edwards et al. Jun 2002 B1
6406474 Neuberger et al. Jun 2002 B1
6409665 Scott et al. Jun 2002 B1
6409723 Edwards Jun 2002 B1
6413267 Dumoulin-White et al. Jul 2002 B1
6416319 Cipolla Jul 2002 B1
6419389 Fuchs et al. Jul 2002 B1
6424852 Zavislan Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6435873 Burgio Aug 2002 B1
6436094 Reuter Aug 2002 B1
6439888 Boutoussov et al. Aug 2002 B1
6440155 Matsumae et al. Aug 2002 B1
6443946 Clement et al. Sep 2002 B2
6443978 Zharov et al. Sep 2002 B1
6447503 Wynne et al. Sep 2002 B1
6447504 Ben-Haim et al. Sep 2002 B1
6451007 Koop et al. Sep 2002 B1
6454790 Neuberger et al. Sep 2002 B1
6459919 Lys et al. Oct 2002 B1
6461296 Desai Oct 2002 B1
6464694 Massengill Oct 2002 B1
6470216 Knowlton Oct 2002 B1
6471712 Burres Oct 2002 B2
6471716 Pecukonis Oct 2002 B1
6475211 Chess et al. Nov 2002 B2
6484052 Visuri et al. Nov 2002 B1
6485413 Boppart et al. Nov 2002 B1
6491685 Visuri et al. Dec 2002 B2
6491715 Abels et al. Dec 2002 B1
6493608 Niemeyer Dec 2002 B1
6494900 Salansky et al. Dec 2002 B1
6497702 Bernaz Dec 2002 B1
6503269 Nield et al. Jan 2003 B2
6503486 Xu et al. Jan 2003 B2
6508785 Eppstein Jan 2003 B1
6508813 Altshuler Jan 2003 B1
6511475 Altshuler et al. Jan 2003 B1
6514243 Eckhouse et al. Feb 2003 B1
6517532 Altshuler et al. Feb 2003 B1
6519376 Biagi et al. Feb 2003 B2
6525819 Delawter et al. Feb 2003 B1
6527716 Eppstein Mar 2003 B1
6527764 Neuberger et al. Mar 2003 B1
6529540 Demmer et al. Mar 2003 B1
6530915 Eppstein et al. Mar 2003 B1
6530916 Shimmick Mar 2003 B1
6537270 Elbrecht et al. Mar 2003 B1
6544257 Nagase et al. Apr 2003 B2
6547780 Sinofsky Apr 2003 B1
6551346 Crossley Apr 2003 B2
6554439 Teicher et al. Apr 2003 B1
6556596 Kim et al. Apr 2003 B1
6558372 Altshuler May 2003 B1
6561808 Neuberger et al. May 2003 B2
6569155 Connors et al. May 2003 B1
6570892 Lin et al. May 2003 B1
6570893 Libatique et al. May 2003 B1
6572634 Koo Jun 2003 B2
6572637 Yamazaki et al. Jun 2003 B1
6595934 Hissong et al. Jul 2003 B1
6600951 Anderson Jul 2003 B1
6602245 Thiberg Aug 2003 B1
6602275 Sullivan Aug 2003 B1
6603988 Dowlatshahi Aug 2003 B2
6605080 Altshuler et al. Aug 2003 B1
6605083 Clement et al. Aug 2003 B2
6606755 Robinson et al. Aug 2003 B1
6607525 France et al. Aug 2003 B2
6610052 Furumoto Aug 2003 B2
6613040 Tankovich et al. Sep 2003 B2
6616447 Rizoiu et al. Sep 2003 B1
6616451 Rizolu et al. Sep 2003 B1
6618531 Goto et al. Sep 2003 B1
6623272 Clemans Sep 2003 B2
6623513 Biel Sep 2003 B2
6629971 McDaniel Oct 2003 B2
6629989 Akita Oct 2003 B2
6632219 Baranov et al. Oct 2003 B1
6635075 Li et al. Oct 2003 B2
6641578 Mukai Nov 2003 B2
6641600 Kohler Nov 2003 B1
6648904 Altshuler et al. Nov 2003 B2
6652459 Payne et al. Nov 2003 B2
6653618 Zenzie Nov 2003 B2
6659999 Anderson et al. Dec 2003 B1
6660000 Neuberger et al. Dec 2003 B2
6663620 Altshuler et al. Dec 2003 B2
6663658 Kollias et al. Dec 2003 B1
6663659 McDaniel Dec 2003 B2
6666856 Connors et al. Dec 2003 B2
6669685 Rizoiu et al. Dec 2003 B1
6675425 Iimura et al. Jan 2004 B1
6676654 Balle-Petersen et al. Jan 2004 B1
6679837 Daikuzono Jan 2004 B2
6682523 Shadduck Jan 2004 B2
6682524 Elbrecht et al. Jan 2004 B1
6685639 Wang et al. Feb 2004 B1
6685699 Eppstein et al. Feb 2004 B1
6685722 Rosenbluth et al. Feb 2004 B1
6689124 Thiberg Feb 2004 B1
6692456 Eppstein et al. Feb 2004 B1
6692517 Cho et al. Feb 2004 B2
6699040 Hahn et al. Mar 2004 B1
6706035 Cense et al. Mar 2004 B2
6709269 Altshuler Mar 2004 B1
6709446 Lundahl et al. Mar 2004 B2
6723090 Altshuler et al. Apr 2004 B2
6724958 German et al. Apr 2004 B1
6726681 Grasso et al. Apr 2004 B2
6736807 Yamazaki et al. May 2004 B2
6743222 Durkin et al. Jun 2004 B2
6746444 Key Jun 2004 B2
6749623 Hsi et al. Jun 2004 B1
6755647 Melikechi et al. Jun 2004 B2
6770069 Hobart et al. Aug 2004 B1
6772053 Niemeyer Aug 2004 B2
6790205 Yamazaki et al. Sep 2004 B1
6801595 Grodzins et al. Oct 2004 B2
6808331 Hall et al. Oct 2004 B2
6808532 Anderson et al. Oct 2004 B2
6824542 Jay Nov 2004 B2
RE38670 Asah et al. Dec 2004 E
6858009 Kawata et al. Feb 2005 B2
6860879 Irion et al. Mar 2005 B2
6860896 Leber et al. Mar 2005 B2
6862771 Muller Mar 2005 B1
6863781 Nocera et al. Mar 2005 B2
6872203 Shafirstein et al. Mar 2005 B2
6878144 Altshuler et al. Apr 2005 B2
6881212 Clement et al. Apr 2005 B1
6887260 McDaniel May 2005 B1
6888319 Inochkin et al. May 2005 B2
6893259 Reizenson May 2005 B1
6902397 Farrell et al. Jun 2005 B2
6902563 Wilkens et al. Jun 2005 B2
6905492 Zvuloni et al. Jun 2005 B2
6916316 Jay Jul 2005 B2
6936046 Hissong et al. Aug 2005 B2
6942658 Rizoiu et al. Sep 2005 B1
6953341 Black Oct 2005 B2
6974450 Weber et al. Dec 2005 B2
6974451 Altshuler et al. Dec 2005 B2
6976985 Altshuler et al. Dec 2005 B2
6986903 Zulli et al. Jan 2006 B2
6989007 Shadduck Jan 2006 B2
6989023 Black Jan 2006 B2
6991644 Spooner et al. Jan 2006 B2
6997923 Anderson et al. Feb 2006 B2
7001413 Butler Feb 2006 B2
7006223 Mullani Feb 2006 B2
7018396 Sierra et al. Mar 2006 B2
7029469 Vasily Apr 2006 B2
7033349 Key Apr 2006 B2
7041094 Connors et al. May 2006 B2
7041100 Kreindel May 2006 B2
7044959 Anderson et al. May 2006 B2
7060061 Altshuler et al. Jun 2006 B2
7066733 Logan et al. Jun 2006 B2
7070611 Biel Jul 2006 B2
7077840 Altshuler et al. Jul 2006 B2
7081128 Hart et al. Jul 2006 B2
7097639 Almeida Aug 2006 B1
7097656 Akopov et al. Aug 2006 B1
7104985 Martinelli Sep 2006 B2
7118562 Furumoto Oct 2006 B2
7118563 Weckwerth et al. Oct 2006 B2
7135033 Altshuler et al. Nov 2006 B2
7144247 Black Dec 2006 B2
7144248 Irwin Dec 2006 B2
7145105 Gaulard Dec 2006 B2
7145108 Kanel et al. Dec 2006 B2
7160289 Cohen Jan 2007 B2
7170034 Shalev Jan 2007 B2
7175617 Jay Feb 2007 B2
7182760 Kubota Feb 2007 B2
7198634 Harth et al. Apr 2007 B2
7202446 Shalev Apr 2007 B2
7204832 Altshuler et al. Apr 2007 B2
7216055 Horton et al. May 2007 B1
7217265 Hennings et al. May 2007 B2
7217267 Jay May 2007 B2
7220254 Altshuler et al. May 2007 B2
7223270 Altshuler et al. May 2007 B2
7223281 Altshuler et al. May 2007 B2
7255691 Tolkoff et al. Aug 2007 B2
7274155 Inochkin et al. Sep 2007 B2
7276058 Altshuler et al. Oct 2007 B2
7280866 McIntosh et al. Oct 2007 B1
7282060 DeBenedictis Oct 2007 B2
7282723 Schomaket et al. Oct 2007 B2
7291140 MacFarland et al. Nov 2007 B2
7291141 Jay Nov 2007 B2
7309335 Altshuler et al. Dec 2007 B2
7311722 Larsen Dec 2007 B2
7322972 Viator et al. Jan 2008 B2
7329273 Altshuler et al. Feb 2008 B2
7329274 Altshuler et al. Feb 2008 B2
7331953 Manstein et al. Feb 2008 B2
7331964 Maricle et al. Feb 2008 B2
7333698 Israel Feb 2008 B2
7351252 Altshuler et al. Apr 2008 B2
7354448 Altshuler et al. Apr 2008 B2
7422598 Altshuler et al. Sep 2008 B2
7423767 Steinsiek et al. Sep 2008 B2
7431419 Turner et al. Oct 2008 B2
7431719 Altshuler et al. Oct 2008 B2
7436863 Matsuda et al. Oct 2008 B2
7500956 Wilk Mar 2009 B1
7531967 Inochkin et al. May 2009 B2
7540869 Altshuler et al. Jun 2009 B2
7553308 Jay Jun 2009 B2
7588547 Deem et al. Sep 2009 B2
7624640 Maris et al. Dec 2009 B2
7647092 Motz et al. Jan 2010 B2
7699058 Jay Apr 2010 B1
7722600 Connors et al. May 2010 B2
7758621 Altshuler et al. Jul 2010 B2
7763016 Altshuler et al. Jul 2010 B2
7839972 Ruchala et al. Nov 2010 B2
7856985 Mirkov et al. Dec 2010 B2
7931028 Jay Apr 2011 B2
7935107 Altshuler et al. May 2011 B2
7938821 Chan et al. May 2011 B2
7942869 Houbolt et al. May 2011 B2
7942915 Altshuler et al. May 2011 B2
7942916 Altshuler et al. May 2011 B2
7998181 Nightingale et al. Aug 2011 B2
8002768 Altshuler et al. Aug 2011 B1
8027710 Dannan Sep 2011 B1
8109924 Altshuler Feb 2012 B2
8182473 Altshuler et al. May 2012 B2
8328794 Altshuler et al. Dec 2012 B2
8328796 Altshuler et al. Dec 2012 B2
8378322 Dahm et al. Feb 2013 B2
20010007068 Ota et al. Jul 2001 A1
20010008973 Van Zuylen et al. Jul 2001 A1
20010016732 Hobart et al. Aug 2001 A1
20010023363 Harth et al. Sep 2001 A1
20010024777 Azar et al. Sep 2001 A1
20010025173 Ritchie et al. Sep 2001 A1
20010029956 Argenta et al. Oct 2001 A1
20010041886 Durkin et al. Nov 2001 A1
20010046652 Ostler et al. Nov 2001 A1
20010048077 Afanassieva Dec 2001 A1
20020002367 Tankovich et al. Jan 2002 A1
20020004066 Stanley et al. Jan 2002 A1
20020005475 Zenzie Jan 2002 A1
20020013572 Berlin Jan 2002 A1
20020016587 Furumoto Feb 2002 A1
20020018754 Sagel et al. Feb 2002 A1
20020019624 Clement Feb 2002 A1
20020019625 Azar Feb 2002 A1
20020026225 Segal Feb 2002 A1
20020029071 Whitehurst Mar 2002 A1
20020032437 Andrews et al. Mar 2002 A1
20020045891 Clement et al. Apr 2002 A1
20020049432 Mukai Apr 2002 A1
20020049483 Knowlton Apr 2002 A1
20020058890 Visuri et al. May 2002 A1
20020071287 Haase Jun 2002 A1
20020071827 Petersen et al. Jun 2002 A1
20020072676 Afanassieva Jun 2002 A1
20020081555 Wiesel Jun 2002 A1
20020090725 Simpson et al. Jul 2002 A1
20020091377 Anderson Jul 2002 A1
20020108193 Gruber Aug 2002 A1
20020111610 Nordquist Aug 2002 A1
20020120256 Furuno et al. Aug 2002 A1
20020123745 Svaasand et al. Sep 2002 A1
20020127224 Chen Sep 2002 A1
20020128635 Altshuler et al. Sep 2002 A1
20020128695 Harth et al. Sep 2002 A1
20020128696 Pearl Sep 2002 A1
20020151878 Shimmick et al. Oct 2002 A1
20020151879 Loeb Oct 2002 A1
20020161357 Anderson Oct 2002 A1
20020161418 Wilkens et al. Oct 2002 A1
20020167974 Kennedy et al. Nov 2002 A1
20020173723 Lewis Nov 2002 A1
20020173777 Sand Nov 2002 A1
20020173780 Altshuler et al. Nov 2002 A1
20020173781 Cense et al. Nov 2002 A1
20020182563 Boutoussov et al. Dec 2002 A1
20020183808 Biel Dec 2002 A1
20020198517 Alfano et al. Dec 2002 A1
20030004499 McDaniel Jan 2003 A1
20030009158 Perricone Jan 2003 A1
20030009205 Biel Jan 2003 A1
20030018373 Eckhardt et al. Jan 2003 A1
20030023235 Cense et al. Jan 2003 A1
20030023283 McDaniel Jan 2003 A1
20030023284 Gartstein et al. Jan 2003 A1
20030028186 Kreintel Feb 2003 A1
20030028227 Neuberger et al. Feb 2003 A1
20030032900 Ella Feb 2003 A1
20030032950 Altshuler et al. Feb 2003 A1
20030036680 Black Feb 2003 A1
20030040739 Koop Feb 2003 A1
20030055413 Altshuler et al. Mar 2003 A1
20030055414 Altshuler et al. Mar 2003 A1
20030057875 Inochkin et al. Mar 2003 A1
20030059738 Neuberger Mar 2003 A1
20030065314 Altshuler et al. Apr 2003 A1
20030073989 Hoey et al. Apr 2003 A1
20030083649 Margaron et al. May 2003 A1
20030084534 Kaizuka May 2003 A1
20030092982 Eppstein May 2003 A1
20030097122 Ganz et al. May 2003 A1
20030100936 Altshuler et al. May 2003 A1
20030104340 Clemans Jun 2003 A1
20030109787 Black Jun 2003 A1
20030109860 Black Jun 2003 A1
20030113684 Scott Jun 2003 A1
20030129154 McDaniel Jul 2003 A1
20030130709 D.C. et al. Jul 2003 A1
20030152528 Singh et al. Aug 2003 A1
20030158550 Ganz et al. Aug 2003 A1
20030163884 Weihrauch Sep 2003 A1
20030167080 Hart et al. Sep 2003 A1
20030169433 Koele et al. Sep 2003 A1
20030181896 Zvuloni et al. Sep 2003 A1
20030187319 Kaneko Oct 2003 A1
20030187383 Weber et al. Oct 2003 A1
20030187486 Savage et al. Oct 2003 A1
20030195494 Altshuler et al. Oct 2003 A1
20030199859 Altshuler et al. Oct 2003 A1
20030216719 Debenedictis et al. Nov 2003 A1
20030216795 Harth et al. Nov 2003 A1
20030232303 Black Dec 2003 A1
20030233138 Spooner Dec 2003 A1
20040006332 Black Jan 2004 A1
20040010298 Altshuler et al. Jan 2004 A1
20040015156 Vasily Jan 2004 A1
20040015158 Chen et al. Jan 2004 A1
20040019120 Vargas et al. Jan 2004 A1
20040019990 Farrell et al. Feb 2004 A1
20040024388 Altshuler Feb 2004 A1
20040024430 Bader et al. Feb 2004 A1
20040030326 Altshuler et al. Feb 2004 A1
20040034319 Anderson et al. Feb 2004 A1
20040034341 Altshuler et al. Feb 2004 A1
20040036975 Slatkine Feb 2004 A1
20040054248 Kimchy et al. Mar 2004 A1
20040073079 Altshuler et al. Apr 2004 A1
20040082940 Black et al. Apr 2004 A1
20040085026 Inochkin et al. May 2004 A1
20040092506 Thompson et al. May 2004 A1
20040093042 Altshuler et al. May 2004 A1
20040093043 Edel et al. May 2004 A1
20040098070 Mohr et al. May 2004 A1
20040105611 Bischel et al. Jun 2004 A1
20040111086 Trombly Jun 2004 A1
20040111132 Shenderova et al. Jun 2004 A1
20040116984 Spooner et al. Jun 2004 A1
20040122311 Cosman Jun 2004 A1
20040133251 Altshuler et al. Jul 2004 A1
20040143181 Damasio et al. Jul 2004 A1
20040143247 Anderson et al. Jul 2004 A1
20040143920 Nanda Jul 2004 A1
20040147984 Altshuler et al. Jul 2004 A1
20040156626 Thoms Aug 2004 A1
20040161213 Lee Aug 2004 A1
20040162490 Soltz et al. Aug 2004 A1
20040162549 Altshuler et al. Aug 2004 A1
20040162596 Altshuler et al. Aug 2004 A1
20040167502 Weckwerth et al. Aug 2004 A1
20040176754 Island et al. Sep 2004 A1
20040186465 Francischelli Sep 2004 A1
20040191729 Altshuler et al. Sep 2004 A1
20040193234 Butler Sep 2004 A1
20040193235 Altshuler et al. Sep 2004 A1
20040193236 Altshuler et al. Sep 2004 A1
20040199079 Chuck et al. Oct 2004 A1
20040199151 Neuberger Oct 2004 A1
20040199227 Altshuler et al. Oct 2004 A1
20040204745 Altshuler et al. Oct 2004 A1
20040208918 Koch et al. Oct 2004 A1
20040210275 Town et al. Oct 2004 A1
20040210276 Altshuler et al. Oct 2004 A1
20040214132 Altshuler Oct 2004 A1
20040225339 Yaroslavsky et al. Nov 2004 A1
20040230258 Altshuler et al. Nov 2004 A1
20040230260 MacFarland et al. Nov 2004 A1
20040234460 Tarver et al. Nov 2004 A1
20040249261 Torchia et al. Dec 2004 A1
20040260210 Ella et al. Dec 2004 A1
20050015077 Kuklin et al. Jan 2005 A1
20050038418 Altshuler et al. Feb 2005 A1
20050049467 Stamatas et al. Mar 2005 A1
20050049582 DeBenedictis et al. Mar 2005 A1
20050049658 Connors et al. Mar 2005 A1
20050063931 Paus et al. Mar 2005 A1
20050065502 Stoltz Mar 2005 A1
20050065531 Cohen Mar 2005 A1
20050074038 Khaydarov Apr 2005 A1
20050080404 Jones et al. Apr 2005 A1
20050085875 Van Zuylen Apr 2005 A1
20050102213 Savasoglu et al. May 2005 A1
20050107849 Altshuler et al. May 2005 A1
20050113815 Ritchie et al. May 2005 A1
20050113890 Ritchie et al. May 2005 A1
20050116673 Carl et al. Jun 2005 A1
20050131400 Hennings et al. Jun 2005 A1
20050143719 Sink Jun 2005 A1
20050143723 Zvuloni et al. Jun 2005 A1
20050154380 DeBenedictis Jul 2005 A1
20050165315 Zuluga et al. Jul 2005 A1
20050165393 Eppstein Jul 2005 A1
20050168158 Inochkin et al. Aug 2005 A1
20050170313 Pitz et al. Aug 2005 A1
20050171517 Altshuler et al. Aug 2005 A1
20050171581 Connors et al. Aug 2005 A1
20050177026 Hoeg et al. Aug 2005 A1
20050177139 Yamazaki et al. Aug 2005 A1
20050177142 Jay Aug 2005 A1
20050182389 LaPorte et al. Aug 2005 A1
20050197681 Barolet et al. Sep 2005 A1
20050203496 Ritchie et al. Sep 2005 A1
20050203497 Speeg et al. Sep 2005 A1
20050215988 Altshuler et al. Sep 2005 A1
20050220726 Pauly et al. Oct 2005 A1
20050222556 Arivra et al. Oct 2005 A1
20050245917 Strassl et al. Nov 2005 A1
20050251116 Steinke et al. Nov 2005 A1
20050251117 Anderson et al. Nov 2005 A1
20050251118 Anderson et al. Nov 2005 A1
20050257612 Hiemer et al. Nov 2005 A1
20050281530 Rizoiu et al. Dec 2005 A1
20060004306 Altshuler et al. Jan 2006 A1
20060004347 Altshuler et al. Jan 2006 A1
20060007965 Tankovich et al. Jan 2006 A1
20060009750 Altshuler et al. Jan 2006 A1
20060013533 Slatkine Jan 2006 A1
20060020309 Altshuler et al. Jan 2006 A1
20060047281 Kreindel Mar 2006 A1
20060052661 Gannot et al. Mar 2006 A1
20060056589 Engelward Mar 2006 A1
20060058712 Altshuler et al. Mar 2006 A1
20060062448 Hirsch et al. Mar 2006 A1
20060079947 Tankovich et al. Apr 2006 A1
20060089687 Spooner et al. Apr 2006 A1
20060094988 Tosaya et al. May 2006 A1
20060100677 Blumenkranz et al. May 2006 A1
20060116671 Slayton et al. Jun 2006 A1
20060118127 Chinn Jun 2006 A1
20060122584 Bommannan et al. Jun 2006 A1
20060122668 Anderson et al. Jun 2006 A1
20060128771 Mirkov et al. Jun 2006 A1
20060149343 Altshuler et al. Jul 2006 A1
20060155266 Manstein et al. Jul 2006 A1
20060161143 Altshuler et al. Jul 2006 A1
20060173480 Zhang Aug 2006 A1
20060194164 Altshuler et al. Aug 2006 A1
20060206103 Altshuler et al. Sep 2006 A1
20060217689 Dick et al. Sep 2006 A1
20060224148 Chou et al. Oct 2006 A1
20060247609 Mirkov et al. Nov 2006 A1
20060253176 Caruso et al. Nov 2006 A1
20060259102 Slatkine Nov 2006 A1
20060265032 Hennings Nov 2006 A1
20060271028 Altshuler et al. Nov 2006 A1
20060282067 Koop et al. Dec 2006 A1
20060287646 Altshuler et al. Dec 2006 A1
20060293727 Spooner et al. Dec 2006 A1
20060293728 Roersma et al. Dec 2006 A1
20070027440 Altshuler et al. Feb 2007 A1
20070038206 Altshuler et al. Feb 2007 A1
20070038271 Cole et al. Feb 2007 A1
20070049910 Altshuler et al. Mar 2007 A1
20070060819 Altshuler et al. Mar 2007 A1
20070060989 Deem et al. Mar 2007 A1
20070067006 Altshuler et al. Mar 2007 A1
20070073308 Anderson et al. Mar 2007 A1
20070078501 Altshuler et al. Apr 2007 A1
20070088206 Peyman Apr 2007 A1
20070093797 Chan et al. Apr 2007 A1
20070105212 Oldham et al. May 2007 A1
20070121069 Andersen et al. May 2007 A1
20070123851 Alejandro et al. May 2007 A1
20070142881 Hennings Jun 2007 A1
20070159592 Rylander et al. Jul 2007 A1
20070173749 Williams et al. Jul 2007 A1
20070179378 Boese et al. Aug 2007 A1
20070179470 Toombs Aug 2007 A1
20070185552 Masotti et al. Aug 2007 A1
20070194717 Belikov et al. Aug 2007 A1
20070198004 Altshuler et al. Aug 2007 A1
20070208252 Makower Sep 2007 A1
20070213696 Altshuler et al. Sep 2007 A1
20070213698 Altshuler et al. Sep 2007 A1
20070213792 Yaroslavsky et al. Sep 2007 A1
20070219602 Ostrovsky et al. Sep 2007 A1
20070219604 Yaroslavsky et al. Sep 2007 A1
20070219605 Yaroslavsky et al. Sep 2007 A1
20070239142 Altshuler et al. Oct 2007 A1
20070239143 Altshuler et al. Oct 2007 A1
20070244527 Hatayama et al. Oct 2007 A1
20070255355 Altshuler et al. Nov 2007 A1
20070260230 Youngquist et al. Nov 2007 A1
20070264625 DeBenedictis Nov 2007 A1
20070288071 Rogers Dec 2007 A1
20080003536 Altshuler et al. Jan 2008 A1
20080004608 Dacquay et al. Jan 2008 A1
20080004611 Houbolt et al. Jan 2008 A1
20080009842 Manstein et al. Jan 2008 A1
20080033516 Altshuler et al. Feb 2008 A1
20080058782 Frangineas et al. Mar 2008 A1
20080058783 Altshuler et al. Mar 2008 A1
20080103565 Altshuler et al. May 2008 A1
20080132886 Cohen et al. Jun 2008 A1
20080139901 Altshuler et al. Jun 2008 A1
20080140164 Oberreiter et al. Jun 2008 A1
20080147054 Altshuler et al. Jun 2008 A1
20080154157 Altshuler et al. Jun 2008 A1
20080154247 Dallarosa Jun 2008 A1
20080172047 Altshuler et al. Jul 2008 A1
20080183162 Altshuler et al. Jul 2008 A1
20080183250 Tanojo et al. Jul 2008 A1
20080186591 Altshuler et al. Aug 2008 A1
20080194969 Werahera et al. Aug 2008 A1
20080195183 Botchkareva et al. Aug 2008 A1
20080208105 Zelickson et al. Aug 2008 A1
20080214988 Altshuler et al. Sep 2008 A1
20080215038 Bakker Sep 2008 A1
20080248554 Merchant et al. Oct 2008 A1
20080262577 Altshuler et al. Oct 2008 A1
20080294150 Altshuler et al. Nov 2008 A1
20080294152 Altshuler et al. Nov 2008 A1
20080294153 Altshuler et al. Nov 2008 A1
20080306471 Altshuler et al. Dec 2008 A1
20080319430 Zenzie et al. Dec 2008 A1
20090018531 Welches Jan 2009 A1
20090018624 Levinson et al. Jan 2009 A1
20090024192 Mulholland Jan 2009 A1
20090024193 Altshuler et al. Jan 2009 A1
20090043294 Island et al. Feb 2009 A1
20090048557 Yeshurun et al. Feb 2009 A1
20090069741 Altshuler et al. Mar 2009 A1
20090132011 Altshuler et al. May 2009 A1
20090137995 Altshuler et al. May 2009 A1
20090149844 Altshuler et al. Jun 2009 A1
20090222068 Oberreiter et al. Sep 2009 A1
20090248004 Altshuler et al. Oct 2009 A1
20090254076 Altshuler et al. Oct 2009 A1
20090287195 Altshuler et al. Nov 2009 A1
20090292277 Sierra et al. Nov 2009 A1
20090312749 Pini et al. Dec 2009 A1
20100010507 Kinoshita Jan 2010 A1
20100015576 Altshuler et al. Jan 2010 A1
20100021867 Altshuler et al. Jan 2010 A1
20100036295 Altshuler et al. Feb 2010 A1
20100049180 Wells et al. Feb 2010 A1
20100109041 Yin et al. May 2010 A1
20100145321 Altshuler et al. Jun 2010 A1
20100195680 Sierra et al. Aug 2010 A1
20100198134 Eckhouse et al. Aug 2010 A1
20100204686 Yaroslavksy et al. Aug 2010 A1
20100217248 Mirkov et al. Aug 2010 A1
20100278756 Chung et al. Nov 2010 A1
20100286673 Altshuler et al. Nov 2010 A1
20100298744 Altshuler et al. Nov 2010 A1
20110046523 Altshuler et al. Feb 2011 A1
20110087155 Uhland et al. Apr 2011 A1
20110137230 Altshuler et al. Jun 2011 A1
20110152847 Mirkov et al. Jun 2011 A1
20110172651 Altshuler et al. Jul 2011 A1
20110184334 Altshuler et al. Jul 2011 A1
20110207075 Altshuler et al. Aug 2011 A1
20110257584 Altshuler et al. Oct 2011 A1
20110267830 Altshuler et al. Nov 2011 A1
20120083862 Altshuler et al. Apr 2012 A1
20120099816 Wilson Apr 2012 A1
20120116271 Caruso et al. May 2012 A1
20120123399 Belikov et al. May 2012 A1
20120277659 Yaroslavsky et al. Nov 2012 A1
20120301842 Altshuler et al. Nov 2012 A1
Foreign Referenced Citations (277)
Number Date Country
400305 Apr 1995 AT
1851583 Mar 1984 AU
2053926 Mar 1990 CN
1073607 Jun 1993 CN
1182572 May 1998 CN
1351483 May 2002 CN
1535126 Oct 2004 CN
2826383 Dec 1979 DE
3304230 Aug 1984 DE
3719561 Jan 1988 DE
8807746 Nov 1988 DE
3837248 May 1990 DE
3841503 Jun 1990 DE
9102407 Jul 1991 DE
19803460 Aug 1999 DE
19944401 Mar 2001 DE
10112289 Aug 2001 DE
10140715 Mar 2002 DE
10120787 Jan 2003 DE
0142671 May 1985 EP
0172490 Feb 1986 EP
0297360 Jan 1989 EP
0320080 Jun 1989 EP
0324120 Jul 1989 EP
0413025 Feb 1991 EP
0458576 Nov 1991 EP
0563953 Oct 1993 EP
0565331 Oct 1993 EP
0575274 Dec 1993 EP
0593375 Apr 1994 EP
0598984 Jun 1994 EP
0709941 May 1996 EP
0724894 Aug 1996 EP
0726083 Aug 1996 EP
0736308 Oct 1996 EP
0743029 Nov 1996 EP
0743029 Nov 1996 EP
0755698 Jan 1997 EP
0763371 Mar 1997 EP
0765673 Apr 1997 EP
0765674 Apr 1997 EP
0783904 Jul 1997 EP
0884066 Dec 1998 EP
0885629 Dec 1998 EP
0920840 Jun 1999 EP
0927544 Jul 1999 EP
1038505 Sep 2000 EP
1057455 Dec 2000 EP
1075854 Feb 2001 EP
1138269 Oct 2001 EP
1138349 Oct 2001 EP
1147785 Oct 2001 EP
1219258 Jul 2002 EP
1226787 Jul 2002 EP
1238683 Sep 2002 EP
1250893 Oct 2002 EP
1250893 Oct 2002 EP
1057454 Nov 2003 EP
1 457 234 Sep 2004 EP
1495735 Jan 2005 EP
1512373 Mar 2005 EP
1535582 Jun 2005 EP
1 627 662 Feb 2006 EP
1650615 Apr 2006 EP
1797836 Jun 2007 EP
1839705 Oct 2007 EP
1854505 Nov 2007 EP
2199453 Apr 1974 FR
2591902 Jun 1987 FR
1251424 Oct 1971 GB
1546625 May 1979 GB
2044908 Oct 1980 GB
2059053 Apr 1981 GB
2059054 Apr 1981 GB
2123287 Feb 1984 GB
2212010 Jul 1989 GB
2239675 Jul 1991 GB
2270159 Mar 1994 GB
2356570 May 2001 GB
2360461 Sep 2001 GB
2360946 Oct 2001 GB
2364376 Jan 2002 GB
2368020 Apr 2002 GB
2390021 Dec 2003 GB
2397528 Jul 2004 GB
5412979 Oct 1979 JP
S5552766 Apr 1980 JP
S55771871 Jun 1980 JP
S574007 Jan 1982 JP
S62165985 Jul 1987 JP
S6323648 Jan 1988 JP
S63249577 Oct 1988 JP
64-027554 Jan 1989 JP
S6481222 Mar 1989 JP
1099574 Apr 1989 JP
H022199 Jan 1990 JP
2174804 Jul 1990 JP
H02285694 Nov 1990 JP
H0319385 Jan 1991 JP
H0316956 Feb 1991 JP
3066387 Mar 1991 JP
H03183184 Aug 1991 JP
199013014 Sep 1991 JP
6022871 Feb 1994 JP
H06154239 Jun 1994 JP
H079179 Jan 1995 JP
7063957 Mar 1995 JP
H07328025 Dec 1995 JP
H0815539 Jan 1996 JP
H0854538 Feb 1996 JP
9084803 Mar 1997 JP
H09141869 Jun 1997 JP
10014661 Jan 1998 JP
10-503109 Mar 1998 JP
10165410 Jun 1998 JP
11047146 Feb 1999 JP
11081877 Mar 1999 JP
2000037400 Feb 2000 JP
2000-153003 Jun 2000 JP
2000300684 Oct 2000 JP
2001000560 Jan 2001 JP
2001029124 Feb 2001 JP
2001145520 May 2001 JP
2001196665 Jul 2001 JP
2001343560 Dec 2001 JP
2002506362 Feb 2002 JP
2002272861 Sep 2002 JP
2003052843 Feb 2003 JP
2005017796 Jan 2005 JP
2003192809 Feb 2005 JP
2006192073 Jul 2006 JP
208233795105406 Jun 1997 RU
208912694012665 Oct 1997 RU
208912794040344 Oct 1997 RU
209605195012749 Nov 1997 RU
21228484954402 Oct 1998 RU
WO 8602783 May 1986 WO
WO 8804592 Jun 1988 WO
WO 9000420 Jan 1990 WO
WO 9006727 Jun 1990 WO
WO 9012548 Nov 1990 WO
WO 9101053 Jan 1991 WO
9102562 Mar 1991 WO
WO 9112050 Aug 1991 WO
WO 9113652 Sep 1991 WO
WO 9113653 Sep 1991 WO
WO 9118646 Dec 1991 WO
WO 9216338 Jan 1992 WO
WO 9203977 Mar 1992 WO
WO 9206739 Apr 1992 WO
WO 9219165 Nov 1992 WO
WO 9305920 Apr 1993 WO
WO 9321843 Nov 1993 WO
WO 9503089 Feb 1995 WO
WO 9504393 Feb 1995 WO
9510243 Apr 1995 WO
WO 9514251 May 1995 WO
WO 9515725 Jun 1995 WO
WO 9532441 Nov 1995 WO
WO 9533518 Dec 1995 WO
WO 9609853 Apr 1996 WO
WO 9618347 Jun 1996 WO
9624406 Aug 1996 WO
WO-9622741 Aug 1996 WO
WO 9623447 Aug 1996 WO
WO 9625979 Aug 1996 WO
WO 9622813 Aug 1996 WO
WO 9624182 Aug 1996 WO
9628212 Sep 1996 WO
WO 9636396 Nov 1996 WO
WO 9641579 Dec 1996 WO
WO 9639734 Dec 1996 WO
WO 9713458 Apr 1997 WO
WO 9713552 Apr 1997 WO
9722384 Jun 1997 WO
9728752 Aug 1997 WO
WO 9737602 Oct 1997 WO
WO 9737723 Oct 1997 WO
9805286 Feb 1998 WO
9806456 Feb 1998 WO
WO 9804317 Feb 1998 WO
WO 9805380 Feb 1998 WO
WO-9807379 Feb 1998 WO
WO-9820937 May 1998 WO
WO 9824507 Jun 1998 WO
9829134 Jul 1998 WO
WO-9841158 Sep 1998 WO
WO 9851235 Nov 1998 WO
WO 9852481 Nov 1998 WO
WO 9858595 Dec 1998 WO
9910046 Mar 1999 WO
WO 9917666 Apr 1999 WO
WO 9917667 Apr 1999 WO
WO-9917668 Apr 1999 WO
WO 9927997 Jun 1999 WO
WO 9929243 Jun 1999 WO
9934867 Jul 1999 WO
WO 9938569 Aug 1999 WO
WO 9939410 Aug 1999 WO
9943387 Sep 1999 WO
9944638 Sep 1999 WO
WO 9946005 Sep 1999 WO
WO 9949937 Oct 1999 WO
WO 9958195 Nov 1999 WO
9962472 Dec 1999 WO
9966988 Dec 1999 WO
WO 0002491 Jan 2000 WO
WO 0003257 Jan 2000 WO
0007514 Feb 2000 WO
0030714 Jun 2000 WO
WO 0032272 Jun 2000 WO
0041278 Jul 2000 WO
WO 0040266 Jul 2000 WO
WO 0043070 Jul 2000 WO
0044294 Aug 2000 WO
WO 0044294 Aug 2000 WO
0054685 Sep 2000 WO
WO 0054649 Sep 2000 WO
WO 0053113 Sep 2000 WO
0062700 Oct 2000 WO
WO 0064537 Nov 2000 WO
WO 0071045 Nov 2000 WO
WO-0066226 Nov 2000 WO
WO 0074583 Dec 2000 WO
WO 0074781 Dec 2000 WO
WO 0078242 Dec 2000 WO
WO 0103257 Jan 2001 WO
0114012 Mar 2001 WO
WO 0126573 Apr 2001 WO
WO 0134048 May 2001 WO
0141872 Jun 2001 WO
WO 0142671 Jun 2001 WO
WO 0154606 Aug 2001 WO
WO 0154770 Aug 2001 WO
0178830 Oct 2001 WO
WO 0178830 Oct 2001 WO
0209813 Feb 2002 WO
0226147 Apr 2002 WO
WO 02053050 Jul 2002 WO
WO 02053050 Jul 2002 WO
WO 02069825 Sep 2002 WO
02078559 Oct 2002 WO
WO 02094116 Nov 2002 WO
03005883 Jan 2003 WO
03049633 Jun 2003 WO
04000150 Dec 2003 WO
WO 03103529 Dec 2003 WO
WO-2004011848 Feb 2004 WO
WO 2004033040 Apr 2004 WO
2004037068 May 2004 WO
2004037287 May 2004 WO
2004080279 Sep 2004 WO
WO 2004073537 Sep 2004 WO
2004086947 Oct 2004 WO
WO 2004084752 Oct 2004 WO
WO 2004086947 Oct 2004 WO
WO 2005007003 Jan 2005 WO
WO 2005009266 Feb 2005 WO
WO 2005030317 Apr 2005 WO
WO-2005046793 May 2005 WO
2005065288 Jul 2005 WO
2005092438 Oct 2005 WO
2005096981 Oct 2005 WO
2005099369 Oct 2005 WO
WO 2005112815 Dec 2005 WO
2006006123 Jan 2006 WO
WO 2006036968 Apr 2006 WO
WO-2006066226 Jun 2006 WO
2006089227 Aug 2006 WO
2006101735 Sep 2006 WO
2006116141 Nov 2006 WO
2007035444 Mar 2007 WO
WO-2007122611 Nov 2007 WO
WO 2008007218 Jan 2008 WO
2008070747 Jun 2008 WO
WO 2008153999 Dec 2008 WO
WO 2010102255 Sep 2010 WO
Non-Patent Literature Citations (215)
Entry
Rylander, C.G. et al., “Mechanical Tissue Optical Clearing Devices: Enhancement of Light Penetration in Ex Vivo Porcine Skin and Adipose Tissue,” Lasers in Surgery and Medicine, vol. 40, pp. 688-694 (2008).
Chan, E.K., “Effects of Compression on Soft Tissue Optical Properties,” IEEE Journal of Selected Topics in Quantum Electronics, vol. 2, No. 4, pp. 943-950 (Dec. 1996).
Ivanov, A.P. et al., “Radiation Propagation in Tissues and Liquids with Close Particle Packing,” Zhurnal Prikladnoi Spektroskopii, vol. 47, No. 4, pp. 662-668 (Oct. 1987).
Apfelberg et al. “Dot or Pointillistic Method for Improvement in Results of Hypertrophic Scarring in the Argon Laser Treatment of Portwine Hemangiomas,” Lasers in Surgery and Medicine, 6:552-558 (1987).
Apfelberg et al. “Analysis of Complications of Argon Laser Treatment for Port Wine Hemangiomas with Reference to Striped Technique,” Lasers in Surgery and Medicine, 2:357-371 (1983).
Dixon et al. “Hypertrophic Scarring in Argon Laser Treatment of Port-Wine Stains,” Plastic and Reconstructive Surgery, 73:771-777 (1984).
Ginsbach et al. “New Aspects in the Management of Benign Cutameous Tumors,” Laser 79 Opto-Electronics, Munich Conference Proceedings, 344-347 (1979).
Greenwald et al. “Comparative Histological Studies of the Tunable Dye (at 577 nm) Laser and Argon Laser: The Specific Vascular Effects of the Dye Laser,” The Journal of Investigative Dermatology, 77:305-310 (1981).
Hulsbergen Henning et al. “Clinical and Histological Evaluation of Portwine Stain Treatment with a Microsecond-Pulsed Dye-Laser at 577 NM,” Lasers in Surgery and Medicine, 4:375-380 (1984).
Hulsbergen Henning et al., “Port Wine Stain Coagulation Experiments with a 540-nm Continuous Wave Dye-Laser,” Lasers in Surgery and Medicine, 2:205-210 (1983).
Osigo et al, “Phase Transitions of Rat Stratum Corneum Lipids by an Electron Paramagnetic Resonance Study and Relationship of Phase States to Drug Penetration,” Biochimica et Biophysica Acta 1301:97-104 (1996).
Rubach et al., “Histological and Clinical Evaluation of Facial Resurfacing Using a Carbon Dioxide Laser With the Computer Pattern Generator,” Arch Otolaryngol Head Neck Surg., 123:929-934 (1997).
Unger, “Laser Hair Transplantation III, Computer-assisted Laser Transplanting,” Dermatol. Surg., 21:1047-1055 (1995).
Sheehan-Dare, et al., “Lasers in Dermatology,” British Journal of Dermatology, 129:1-8 (1993).
Rotteleur, et al., “Robotized scanning laser handpiece for the treatment of port wine stains and other angiodysplasias,” Lasers Surg. Med., 8:283-287 (1998).
Nemeth, et al., “Copper vapor laser treatment of pigmented lesions,” Lasers Surg. Med. Supp. 2:51 (1990).
McDaniel, et al., “Hexascan: A New Robotized Scanning Laser Handpiece,” Cutis, 45:300-305 (1990).
Levin, G. et al., “Designing with hyseretic current-mode control, ” EDN Magazine, pp. 1-8, Apr. 28, 1994.
Levin, G. et al., “Designing with hyseretic current-mode control, ” EDN Magazine, pp. 1-8, Apr. 11, 1996.
Gottlieb, I., “Power Supplies, Switching Regulators, Inverters & Converters,” 1976.
Shumilovitch et al., “Influence of Low Intensity Laser Radiation Upon the Microflora of Carious Cavities and Root Canal,” SPIE vol. 1984, pp. 215-220.
Sandford et al., “Thermal Effects During Desensitisation of Teeth with Gallium—Aluminum—Arsenide Lasers,” University of Queensland Dental School, Periodontology 15: 25-30 (1994).
Forrest-Winchester et al., “The Effect of Infrared Laser Radiation on Dentinal Permeability in vitro,” Department of Dentistry, University of Queensland Dental School, pp. 1-8, 1992.
Powell, “Laser Dental Decay Prevention: does it have a future?” SPIE vol. 3192, 1997.
Westerman et al., “Argon Laser Irradiation Effects on Sound Root Surfaces: In Vitro Scanning Electron Microscopic Observations,” Journal of Clinical Laser Medicine and Surgery, vol. 16, No. 2, pp. 111-115, 1998.
Blankenau et al., “In Vivo Caries-Like Lesion Prevention with Argon Laser: Pilot Study,” Journal of Clinical Laser Medicine and Surgery, vol. 17, No. 6, pp. 241-243, 1999.
Hsu et al., “Combined Effects of Laser Irradiation/Solution Flouride Ion on Enamel Demineralization,” Journal of Clinical Laser Medicine and Surgery, vol. 16, No. 2 pp. 93-105, 1998.
Hicks et al., “After Low Fluence Argon Laser and Flouride Treatment,” Compendium, vol. 18, No. 6, Jun. 1997.
Hicks et al., “Enamel Carries Initiation and Progression Following Low Fluence (energy) and Argon Laser and Fluoride Treatment,” The Journal of Clinical Pediatric Dentistry, vol. 20, No. 1 pp. 9-13, 1995.
Oleinik, et al., “Automatized Securing Definition for Laser Therapy Indications in Case of Non-complicated Caries,” SPIE, vol. 1984, pp. 238-244.
Kazmina et al., “Laser Prophlaxis and Treatment of Primary caries,” SPIE vol. 1984, pp. 231-233.
Sokolova et al., “Low-intense Laser Radiation in Complex Treatment of Inflammatory Diseases of Parodontium,” SPIE vol. 1984, pp. 234-237.
Petrischev et al. “Clinical and Experimental Low-Intense Laser Therapy in Dentistry,” SPIE, vol. 1984, pp. 212-214.
Mamedova et al., “Microbiological Estimate of Parodontis Laser Therapy Efficiency,” SPIE vol. 1984, pp. 247-249.
Kozlov et al., “Laser in Diagnostics and Treatment of Microcirculation Disorders Under Parodontitis,” SPIE vol. 1984, pp. 253-264.
Kalivradzhiyan et al., “The Usage of Low Intensity Laser Radiation for the Treatment of the Inflammatory processes of the Oral Cavity Mucosa after Applying Removable Plate Dentures,” SPIE vol. 1984 pp. 225-230.
Walsh, “Laser “Curettage”: a Critical Analysis,” Periodontology 14:4-12, 1993.
Ozawa et al., “Stimulatory Effects of Low-Power Laser Irradiation on Bone Formation in vitro,” SPIE vol. 1984, pp. 281-288.
Shimizu et al., “Prospect of Relieving Pain Due to Tooth Movement During Orthodontic Treatment Utilizing a GA-AI as Diode Laser,” SPIE vol. 1984, pp. 275-280.
Petrischev et al., “Report on Low Intensity Laser Radiation Usage in Dentistry,” SPIE vol. 1984, pp. 202-211.
Karu, “Photobiological Fundamentals of Low-Power Laser Therapy,” 8th Congress of International Society for Laser Surgery and Medicine, Mar. 30, 1987.
Schindl, “Does Low Intensity Laser Irradiation Really Cause Cell Damage?” Laser in Surgery and Medicine vol. 22, pp. 105, 2001.
Grossman, et al., “780 nm Low Power Diode Laser Irradiation Stimulates Proliferation of Keratinocyte Cultures: Involvement of Reactive Oxygen Species,” Lasers in Surgery and Medicine vol. 29, pp. 212-218, 1998.
Karu, “Cell Attachment to Extracellular Matrics is Modulated by Pulsed Radiation at 820 nm and Chemicals that Modify the Activity of Enzymes in the Plasma Membrane,” Laser in Surgery and Medicine, vol. 29, pp. 274-281, 2001.
Maegawa, et al., “Effects of Near-Infrared Low-Level Laser Irradiation on Microcirculation,” Lasers in Surgery and Medicine, vol. 27, pp. 427-437, 2000.
Van Bruegel, “Power Density and Exposure Time of He—Ne Irradiation Are More Important Than Total Energy Dose in Photo-Biomodulation of Human Fibroblasts in Vitro,” Lasers in Surgery and Medicine, vol. 12 pp. 528-537, 1992.
European Summons to Attend Oral Proceedings issued Aug. 13, 2012 for Application No. 03737199.4 (4 Pages).
European Search Report, European Patent Application No. 10012969.1, Dated Jul. 13, 2011.
[No Author] Webpage www.gallery.com—Rutile (Titanium Oxide)—Retrieved Oct. 3, 2011 from Http://www.galleries.com/minerals/oxides/rutile/rutile.htm. 2 pages.
IPG Data Sheet for TFL Thulium Laser, Jun. 2001.
Altea Therapeutics—Medicines Made Better (single page website print-out), Sep. 30, 2004.
G.B. Altshuler et al., “Acoustic response of hard dental tissues to pulsed laser action,” SPIE, vol. 2080, Dental Application of Lasers, pp. 97-103, 1993.
G.B. Altshuler et al., “Extended theory of selective photothermolysis,” Lasers in Surgery and Medicine, vol. 29, pp. 416-432, 2001.
R.L. Amy & R. Storb, “Selective mitochondrial damage by a ruby laser microbeam: An electron microscopic study,” Science, vol. 15, pp. 756-758, Nov. 1965.
R.R. Anderson et al., “The optics of human skin,” Journal of Investigative Dermatology, vol. 77, No. 1, pp. 13-19, 1981.
R.R. Anderson & J.A. Parrish, “Selective photothermolysis: Precise microsurgery by selective absorption of pulsed radiation,” Science, vol. 220, pp. 524-527, Apr. 1983.
A.V. Belikov et al., “Identification of enamel and dentine under tooth laser treatment,” SPIE vol. 2623, Progress in Biomedical Optics Europe Series, Proceedings of Medical Applications of Lasers III, pp. 109-116, Sep. 1995.
P. Bjerring et al., “Selective Non-Ablative Wrinkle Reduction by Laser,” J Cutan Laser Ther, vol. 2, pp. 9-15, 2000.
Derma Chiller advertisement (2 pages) from Paradigm Trex.
Doukas et al., “Transdermal Drug Delivery With a Pressure Wave,” Advanced Drug Delivery Reviews 56 (2004), pp. 559-579.
J.S. Dover et al., “Pigmented guinea pig skin irradiated with Q-switched ruby laser pulses,” Arch Dermatol, vol. 125, pp. 43-49, Jan. 1989.
L.H. Finkelstein & L.M. Blatstein, “Epilation of hair-bearing urethral grafts using the neodymium:yag surgical laser,” Journal of Urology, vol. 146, pp. 840-842, Sep. 1991.
E.J. Fiskerstrand et al., “Hair Removal With Long Pulsed Diode Lasers: A Comparison Between Two Systems With Different Pulse Structures,” Lasers in Surgery and Medicine, vol. 32, pp. 399-404, 2003.
L. Goldman, Biomedical Aspects of the Laser, Springer-Verlag New York Inc., publishers, Chapts. 1, 2, & 23, 1967.
L. Goldman, “Dermatologic manifestations of laser radiation,” Proceedings of the First Annual Conference on Biologic Effects of Laser Radiation, Federation of American Societies for Experimental Biology, Supp. No. 14, pp. S-92-S-93, Jan.-Feb. 1965.
L. Goldman, “Effects of new laser systems on the skin,” Arch Dermatol., vol. 108, pp. 385-390, Sep. 1973.
L. Goldman, “Laser surgery for skin cancer,” New York State Journal of Medicine, pp. 1897-1900, Oct. 1977.
L. Goldman, “Surgery by laser for malignant melanoma,” J. Dermatol. Surg. Oncol., vol. 5, No. 2, pp. 141-144, Feb. 1979.
L. Goldman, “The skin,” Arch Environ Health, vol. 18, pp. 434-436, Mar. 1969.
L. Goldman & D.F. Richfield, “The effect of repeated exposures to laser beams,” Acta derm.-vernereol., vol. 44, pp. 264-268, 1964.
L. Goldman & R.J. Rockwell, “Laser action at the cellular level,” JAMA, vol. 198, No. 6, pp. 641-644, Nov. 1966.
L. Goldman & R.G. Wilson, “Treatment of basal cell epithelioma by laser radiation,” JAMA, vol. 189, No. 10, pp. 773-775.
L. Goldman et al., The biomedical aspects of lasers, JAMA, vol. 188, No. 3, pp. 302-306, Apr. 1964.
L. Goldman et al., “Effect of the laser beam on the skin, Preliminary report” Journal of Investigative Dermatology, vol. 40, pp. 121-122, 1963.
L. Goldman et al., “Effect of the laser beam on the skin, III. Exposure of cytological preparations,” Journal of Investigative Dermatology, vol. 42, pp. 247-251, 1964.
L. Goldman et al., “Impact of the laser on nevi and melanomas,” Archives of Dermatology, vol. 90, pp. 71-75, Jul. 1964.
L. Goldman et al., “Laser treatment of tattoos, A preliminary survey of three year's clinical experience,” JAMA, vol. 201, No. 11, pp. 841-844, Sep. 1967.
L. Goldman et al., “Long-term laser exposure of a senile freckle,” ArchEnviron Health, vol. 22, pp. 401-403, Mar. 1971.
L. Goldman et al., “Pathology, Pathology of the effect of the laser beam on the skin,” Nature, vol. 197, No. 4870, pp. 912-914, Mar. 1963.
L. Goldman et al., “Preliminary investigation of fat embolization from pulsed ruby laser impacts of bone,” Nature, vol. 221, pp. 361-363, Jan. 1969.
L. Goldman et al., “Radiation from a Q-switched ruby laser, Effect of repeated impacts of power output of 10 megawatts on a tattoo of man,” Journal of Investigative Dermatology, vol. 44, pp. 69-71, 1965.
L. Goldman et al., “Replica microscopy and scanning electron microscopy of laser impacts on the skin,” Journal of Investigative Dermatology, vol. 52, No. 1, pp. 18-24, 1969.
M.C. Grossman et al., “Damage to hair follicles by normal-mode ruby laser pulses,” Journal of he American Academy of Dermatology, vol. 35, No. 6, pp. 889-894, Dec. 1996.
M.C. Grossman et al., “Laser Targeted at Hair Follicles,” Lasers Med Surg., Suppl. 7:221,1995.
E. Klein et al., “Biological effects of laser radiation 1.,”Northeast Electroncis Research and Engineering Meeting, NEREM Record, IEEE catalogue No. F-60, pp. 108-109, 1965.
J.G. Kuhns et al., “Laser injury in skin,” Laboratory Investigation, vol. 17, No. 1, pp. 1-13, Jul. 1967.
J.G. Kuhns et al., “Biological effects of laser radiation II Effects of laser irradiation on the skin,” NEREM Record, pp. 152-153, 1965.
D. Manstein et al., “Selective Photothermolysis of Lipid-Rich Tissue,” American Society for Laser Medicine and Surgery Abstracts, No. 17, American Society for Laser Medicine and Surgery Twenty-First Annual Meeting, Apr. 20-22, 2001, p. 6.
R.J. Margolis et al., “Visible action spectrum for melanin-specific selective photothermolysis,” Lasers in Surgery and Medicine, vol. 9, pp. 389-397, 1989.
Ohshiro et al., “The Ruby and Argon Lasers in the Treatment of the Naevi,” Annals Academy of Medicine, Apr. 1983, vol. 12, No. 2, pp. 388-395.
J.A. Parrish, “Selective thermal effects with pulsed irradiation from lasers: From organ to organelle,” Journal of Investigative Dermatology, vol. 80, No. 6 Supplement, pp. 75s-80s, 1983.
L. Polla et al., “Melanosomes are a primary target of Q-switched ruby laser irradiation in guinea pig skin,” Journal of Investigative Dermatology, vol. 89, No. 3, pp. 281-286, Sep. 1987.
Riggle et al., “Laser Effects on Normal and Tumor Tissue,” Laser Applications in Medicine and Biology, vol. 1, M.L. Wolbarsht, editor, Plenum Press, publishers, Chapter 3, pp. 35-65, 1971.
T. Shimbashi & T. Kojima, “Ruby laser treatment of pigmented skin lesions,” Aesth. Plast. Surg., vol. 19, pp. 225-229, 1995.
Stratton, K., et al., “Biological Effects of Laser Radiation II: ESR Studies of Melanin Containing Tissues after Laser Irradiation,” Northeast Electronics Research and Engineering Meeting—NEREM Record, IEEE Catalogue No. F-60, pp. 150-151, Nov. 1965.
Sumian, C.C. et al., “A Preliminary Clinical and Histopathological Study of Laser Skin Resurfacing Using a Frequency-Doubled Nd:YAG Laser After Application of Chromofilm®,” Journal of Cutaneous Laser Therapy, vol. 1, pp. 159-166, 1999.
Sumian, C.C. et al., “Laser Skin Resurfacing Using a Frequency Doubled Nd:YAG Laser After Topical Application of an Exogenous Chromophore,” Lasers in Surgery and Medicine, vol. 25, pp. 43-50, 1999.
C.R. Taylor et al., “Treatment of tattoos by Q-switched ruby laser,” Arch. Dermatol. vol. 126, pp. 893-899, Jul. 1990.
V.V. Tuchin, “Laser light scattering in biomedical diagnostics and therapy,” Journal of Laser Applications, vol. 5, No. 2-3, pp. 43-60, 1993.
S. Watanabe et al, “Comparative studies of femtosecond to microsecond laser pulses on selective pigmented cell injury in skin,” Photochemistry and Photobiology, vol. 53, No. 6, pp. 757-762, 1991.
A.J. Welch et al., “Evaluation of cooling techniques for the protection of the epidermis during HD-yag laser irradiation of the skin,” Neodymium-Yag Laser in Medicine and Surgery, Elsevier Science Publishing Co., publisher, pp. 195-204, 1983.
R.B. Yules et al., “The effect of Q-switched ruby laser radiation on dermal tattoo pigment in man,” Arch Surg, vol. 95, pp. 179-180, Aug. 1967.
E. Zeitler and M. L. Wolbarsht, “Laser Characteristics that Might be Useful in Biology,” Laser Applications in Medicine and Biology, vol. I, M.L. Wolbarsht, editor, Plenum Press, publishers, Chapter 1, pp. 1-18, 1971.
Abstracts Nos. 17-19, Lasers in Surgery and Medicine, ASLMS, American Society for Laser Medicine and Surgery, Apr. 20, 2001.
Abstracts Nos. 219-223, ASLMS, American Society for Laser Medicine and Surgery, Apr. 20, 2001.
Invention description to certificate of authorship, No. 532304, “The way of investigation of radiation time structure of optical quantum generator”, Sep. 7, 1974.
Invention description to certificate of authorship, No. 719439, “The ring resonator of optical quantum generator”, Aug. 15, 1975.
Invention description to certificate of authorship, No. 741747, “The modulator of optical radiation intensity”, Oct. 10, 1977.
Invention description to certificate of authorship, No. SU 1257475 A1, “Laser interferometric device to determine no-linearity of an index of refraction of optical medium”, Sep. 4, 1985.
Invention description to certificate of authorship, No. SU 1326962 A1, “The way of determination of non-linearity of an index of refraction of optical medium”, Mar. 31, 1986.
Altshuler et al., “Modern Optics and Dentistry,” Laser in Dentistry, pp. 283-297, 1995.
Altshuler et al., “New Optical Effects in the Human Hard Tooth Tissues,” Lasers and Medicine, Proc. SPIE vol. 1353, pp. 97-102, 1989.
Altshuler et al., “Human Tooth as an Optical Device,” SPIE vol. 1429 Holography and Interferometry and Optical Pattern Recognition in Biomedicine, pp. 95-104, 1991.
Ohbayashi, “Stimulatory Effect of Laser Irradiation on Calcified Nodule Formation in Human Dental Pulp Fibroblasts,” Abstract J-Endod. Jan. 1999; 25(1): 30-3.
Orchardson, “Effect of Pulsed Nd:YAG Laser Radiation on Action Potential Conduction in Nerve Fibres Inside Teeth in vitro,” Abstract J-Dent. Jul.-Aug. 1998; 26(5-6): 421-6.
Dabrowska, “Intravital Treatment of the Pulp with Stimulation Laser Biostimulation,” Abstract Rocz-Akad-Med-Bialymst. 1997; 42(1): 168-76.
Sing, “Electroacupuncture and Laser Stimulation Treatment: Evaluation by Somatosensory Evoked Potential in Conscious Rabbits,” Abstract Am-J-Chin-Med. 1997; 25(3-4): 263-71.
Walsh, “The Current Status of Low Level Laser Therapy in Dentistry. Part 1. Soft Tissue Applications” paper prepared by LJ Walsh, Department of Dentistry University of Queensland, pp. 1-16. Publication date unknown.
Zonios et al., “Skin Melanin, Hemoglobin, and Light Scattering Properties can be Quantitatively Assessed in Vivo Using Diffuse Reflectance Spectroscopy,” Journal of Investigative Dermatology, V. 117: 1452-1457 (Dec. 2001).
Remillard et al., “Diode laser illuminated automotive brake lamp using a linear fanout diffractive optical element,” Proc. of the Diffractive Optics and Micro-Optics Conference, OSA Technical Digest Series vol. 10, 192-194 (1998).
Remillard et al., “Diode Laser Illuminators for Night-Vision Applications,” SPIE Proceedings vol. 4285:14-22 (2001).
Marinelli et al., “Diode laser illuminated automotive lamp systems,” SPIE Proceedings vol. 3285:170-177 (1998).
Rohrer, “Evaluating the Safety and Efficacy of a Novel Light Based Hair Removal System,” Lasers. Surg. Med. Supp.13:97 (2001).
Sliney et al., “Safety with Lasers and Other Optical Sources: A Comprehensive Handbook,” Plenum Press, pp. 477-480 (1980).
Watanabe, S. et al., “The Effect of Pulse Duration on Selective Pigmented Cell Injury by Dye Lasers,” The Journal of Investigative Dermatology, 88:523, 1987.
“Bioptron Light Therapy System,” website print-out, accessed Jul. 13, 2006 (2 pages).
[No Author] Energy Systems Coropration, “A Practical Guide for the PhotoDern.RTM.VL user,” Haifa, Israel, Commercial Brochure 8 Pages, Oct. 1995.
[No Author] “Final Report on the LFDL-10 Laser System for the GCA Corporation,” Candela Corp., Natick, MA, Section II, subsection 5, pp. 13-15 & 27, Mar. 1982.
[No Author] “Fractional Photothermolysis Redefines Facial Skin Regeneration Science,” Aesthetic Buyers Guide, Mar./Apr. 2004, www.miinews.com, pp. 1-4.
[No Author] “Hydrogel Dressings Contain Particles During Laser Therapy,” Dermatology Times, ISSN-01966197, p. 26 (1994).
[No Author] “Instruction Manual, TFDL-10,” Adapted for SLAC, Candela Corporation, Natick, Oct. 1985.
[No Author] “Lasers Battle for Prostatectomy Market,” Medical Laser Industry Report, 5:1-3 (Aug. 1991).
[No Author] “LFDL-8 Instruction Manual,” Candela Laser Corporation, Wayland, MA Revised Oct. 1987.
[No Author] “LFDL-8 Instruction Manual,” Candela Laser Corporation, Wayland, MA, Jan. 1982, Revised Jun. 1987.
[No Author] “LFDL-8 Instruction Manual,” Cynosure, Inc., Bedford, MA, Revised Nov. 1992.
[No Author] “Prostate Enlargement: Benigh Prostatic Hyperplasia,” brochure from U.S. Department of Health and Human Services, pp. 1-14, (at least by 1992).
[No Author] “Special Instruction and Test Results for the LFDL-2 Wave Guide Laser,” Candela Laser Corporation, Wayland, MA, Sep. 1982.
[No Author] “The Laser TURP Advantage,” INTRA-SONIX, Inc. pp. 1-4 (1991).
[No Author] Beckman Laser Institute “Experimental PDT to Prevent Esophegus Cancer,” (8 pages) 1996.
[No Author] Cynosure Dioderm 510(k) Notification K992765 for Cynosure, Inc. to Food and Drug Administration, dated: Aug. 16, 1999 and Aug. 20, 1999 (Additional Information).
[No Author] Reliant Technologies, Inc. “Physicians Guide: Understanding Fraxel Laser Treatment,” pp. 1-10 (2004).
[No Author] Ritter Sybron Corporation, “Electrosurgery, A Guide for Operating Room Personnel,” pp. 1-22, (Jun. 1976).
[No Author] Selective Photothermolysis of Sebaceous Glands, Department of Health and Human Services, Public Health Service, Small Business Innovation Research Program II Grant Application, Cynosure, Inc., dated: Jul. 27, 2000, pp. 17-39 and 43-44.
“American Society for Laser Medicine and Surgery Abstracts,” Lasers in Surgery and Medicine, Supplement 6, p. 46 (1994).
Anderson, R.R., et al., “Microvasculature Can Be Selectively Damaged Using Dye Lasers: A Basic Theory and Experimental Evidence in Human Skin,” Lasers in Surgery and Medicine 1:263-276 (1981).
Altshuler, et al., “Self Canalization of Laser Microbeam in Tissue as Fundamental Mechanism of Fractional Skin Resurfacing”, Lasers in Surgery and Medicine Supple 15, 21, 2003.
Angelis, et al., “Fractional, Non-Ablative Laser Therapy for the Treatment of Striae Distensae”, White Paper published by Palomar Medical Technologies, Inc. (2009)5 pages.
Apfelberg, D.B., “A Preliminary Study of the Combined Effect of Neodymium:YAG Laser Photocoagulation and Direct Steroid Instillation in the Treatment of Capillary/Cavernous Hemangiomas of Infancy,” Department of Plastic Surgery and Comprehensive Laser Center, Palo Alto Medical Foundation, Palo Alto, CA, pp. 94-103 (1989).
Apfelberg, D.B., “Combination Treatment for Massive Cavernous Hemangioma of the Face: YAG Laser Photocoagulation Pulse Direct Steroid Injection Followed by YAG Laser Resection with Sapphire Scalpel Tips, Aided by Superselective Embolization,” Lasers in Surgery and Medicine, 10:217-223 (1990).
Benjavitvilai, C. et al., “Fuzzy Calibration of Magnetometer in Presence of Surgical Microscope,” 2005 27th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (IEEE Cat. No. 05CH37611C), Shanghai, China, Aug. 31-Sep. 3, 2005.
Bogdan Allemann, et al., “Laser Principles”, Physical and Electronic Properties of Lasers, Basics in Dermatological Laser Applications, Curr. Probl. Dermatol, Basel, Karger. Zurich, Switzerland and Miami, Florida. vol. 42, pp. 7-23, 2011, 17 pages.
Bohm et al., “The Pilosebaceous Unit is Part of the Skin Immune System,” Dermatology, 196:75-79, 1998.
Boiteux, M., et al., “A Transverse Flow Repetitive Dye Laser,” Applied Optics, 9, 514 (1970).
Boulnois, J., “Photophysical Processes in Recent Medical Laser Developments: a Review,” Lasers in Medical Science, vol. 1:47-66 (1986).
Britt et al., “The Effect of pH or Photobleaching of Organic Laser Dyes”, IEEE J. Quantum Electron. (Dec. 1972), 913-914.
Burlamacchi et al, “A Simple Reliable Waveguide Dye Laser for Ophthalmological Applications,” Rev of Sci Instrum; vol. 46; No. 3; pp. 281-283, Mar. 1975.
Costello, A. et al., “Nd:YAG Laser Ablation of the Prostate as a Treatment for Benign Prostatic Hypertrophy,” Lasers in Surgery and Medicine, 12:121-124 (1992).
Cunliffe, “Acne Vulgaris. The Past, the Present and the Future,” Acta Bermatovener (Stockh) Suppl. 120, pp. 34-38, 1985.
Dierickx, C.C. et al., “Thermal Relaxation of Port-wine Stain Vessels Probed In Vivo: The Need for 1-10 Millisecond Laser Pulse Treatment,” The Journal for Investigative Dermatology, pp. 709-714 (1995).
Dock et al., “Clinical Histologic and Ultrastructural Evaluation of Solar Elastosis Treated With the Pulsed Dye Laser,” American Society for Laser Medicine and Surgery Abstracts, p. 54 (Apr. 1997).
Dufresne et al., “Squamous cell carcinoma arising from the follicular occlusion triad,” J. Am. Acad. Dermatol. 35(3), Part 1:475-477, 1996.
Fallon Friedlander, “Effective Treatment of Acne Fulminans-Associated Granulation Tissue with the Pulsed Dye Laser,” Pediatric Dermatology, 15(5):396-398, 1998.
Ellenberger, et al. “Single-Frequency Nd:Glass Laser Oscillator with Pulse-Transmission-Mode Q-Switch with Pulse-Transmission-Mode Q-Switch,” Optics communication, vol. 81, No. 6 (Mar. 1991).
Fletcher, A.N. et al., “Improving the Output and Lifetime of Flashlamp-Pumped Dye Lasers” Proceedings of the International Conference on Lasers '85, pp. 797-804, Dec. 2-6, 1985.
Friedman-Binrbaum et al., “Seborrheic Skin and Acne Vulgaris as Protective Factors against the Development of Basal Cell Epithelioma,” Dermatolgica, 183:160-163, 1991.
Furomoto, H., “Dye Chemisry and System Study for Optimum Laser Operation at 436 NM Using the LFDL-10 Laser,” Prepared for Burlington Division Geophysical Corporation of America, pp. 1-23, Mar. 1982.
Goldberg, “Lasers for Facial Rejuvenation”, Am J. Clin. Dermatol., 4(4):225-234, 2003, 10 pages.
Goldberg, “Nonablative Resurfacing”, Clinics in Plastic Surgery, Skin Laser and Surgery Specialists of New York and New Jersey. Westwood, New Jersey. vol. 27, No. 2, Apr. 2000, 6 pages.
Goldman, M. P., “Leg Veins and Lasers,” American Society for Laser Medicine and Surgery Abstracts, Fourteen Annual Meeting, Toronto, Ontario, Canada, p. 48 (Apr. 8-10, 1994).
Goldman, M.P., “Sclerotherapy—Treatment of Varicose and Telangiectatic Leg Veins,” Second Edition, Mosby, pp. 454-467 (No Date Given).
Haedersal, et el., “Fractional Nonablative 1540 nm Laser Resurfacing for Thermal Burn Scars: A Randomized Controlled Trial”, Lasers in Surgery and Medicine, 41:189-195, 2009, 7 pages.
Johnsson et al., “No photoinactivation of Propionibacterium acnes with soft laser treatment,” Dermatologica, 175(1):50, 1987.
Kandel, Laurence B., M.D., et al., “Transurethral Laser Prostatectomy in the Canine Model,” Lasers in Surgery and Medicine, 12:33-42 (1992).
Kantor et al., “Treatment of acne keloidalis nuchae with carbon dioxide laser,” J. Am. Acad. Dermatol., 14:263-267, 1986.
Kelly et al., “Nonablative Laser Treatment of Facial Rhytides: United States Phase II Clinical Study,” American Society for Laser Medicine and Surgery Abstracts, p. 38, No date given.
Kilmer et al., “Pulse Dye Laser Treatment of Rhytids,” American Society for Laser Medicine and Surgery Abstracts, p. 44 (Apr. 1997).
Korobov et al., “Dependence of the Quantum Yield of Intercombinational Conversion into the Triplet State of Rhodamine 6G on the pH of the Medium”, Zhur. Prikl. Spektrosk. 24(1) 28-31 (Jan. 1976).
Krames et al. (2007) “Status and Future of High-Power Light-Emitting Diodes for Solid State Lighting,” J. Display Technol., 3(2):160-175.
Leger, J. et al., “Geometrical Transformation of Linear Diode-Laser Arrays for Longitudinal Pumping of Solid-State Lasers,” IEEE Journal of Quantum Electronics, vol. 28, No. 4, Apr. 1992.
Lesnik et al., “Agents that cause enlargement of sebaceous glands in hairless mice,” Arch. Dermatol., 284:100-105, 1992.
Lucchina et al., “Fluorescence photography in the evaluation of acne,” J. Am. Acad. Dermatol. 35:58-63 (1996).
Manstein, D., et al., “Fractional Photothermolysis: A New Concept for Cutaneous Remodeling Using Microscopic Patterns of Thermal Injury,” Lasers in Surgery and Medicine, 34: 426-438 (2004).
Manuskiatti et al., “Laser hair removal affects sebaceous glands and sebum excretion . . . ,” J. Am. Acad. Dermatol., 41:176-180, 1999.
Matsunaga et al., “Effect of pH on Dye-Laser Output Power”, J. Appl. Phys. 48(2):842-844 (Feb. 1977).
McCullough, David L., M.D., “Transurethral Laser Treatment of Benign Prostatic Hyperplasia,” and “Transurethral Ultrasound-guided Laser-Induced Prostatectomy (TULIP) Procedure): A Canine Prostate Feasibility Study,” by Roth, Robert A., M.D., et al., The Journal of Urology, 146:1126-1135 (1991).
McNicholas, T. A., et al., “Interstitial Laser Coagulation of the Prostate: Experimental Studies,” SPIE, 1421:30-35 (1991). (From Proceedings of Lasers in Urol., Laparoscopy, and General Surgery, Jan. 21-23, 1991).
Moretti, Michael, “Holmium Boosts Orthopedic Laser Development,” Medical Laser Buyers Guide, p. 93 (1992).
Moretti, Michael, “Lasers Improve Prostatectomy Treatment,” Medical Laser Buyers Guide, p. 94-96 (1992).
Mostovnikov, V.A. et al., “Recovery of Lasing Properties of Dye Solutions after Their Photolysis,” Sov. J. Quantum Electron, 6(9), Sep. 1976, pp. 1126-1128.
Nanni, C.A. et al., “Complications of Carbon Dioxide Laser Resurfacing,” Washington Inst. of Dermatol. Surg. 24:315-320 (1998).
Overholt BF et al. “Balloon photodynamic therapy of esophageal cancer: effect of increasing balloon size.” PubMed; Lasers Surg Med. 1996, 18(3):248-52.
Panjehpour M et al. “Spectroscopic diagnosis of esophageal cancer: new classification model, improved measurement system.” PubMed; Gastrointest Endosc. Jun. 1995; 41 (6):577-81.
Polanyi, Thomas & Tobias, Irwin, Lasers—A Series of Advances, Edited by A.K. Levine, vol. 2, Marcel Dekker, Inc, N.Y., 1968, pp. 400, 402-403 & 422.
Reed J.T. et al., “Treatment of Periorbital Wrinkles,” Washington Inst. of Dermatol. Surg. 23:643-648 (1997).
Rosenfeld, H., et al., “Treatment of Cutaneous and Deep Vascular Lesions with the Nd:YAG Laser,” Lasers in Surgery and Medicine, 6:20-23 (1986).
Russel et al. “Flash-Lamp-Excited Self-Injection-Seeded Q-Switch Ti:Al2O3 Laser Oscillator,” Applied Optics, vol. 35, No. 24 (Aug. 1996).
Schade, W. et al., “Temperature tuned distributed feedback dye laser with high repetition rate”, Applied Optics, vol. 29, No. 27, Sep. 20, 1990, pp. 3950-3954.
Schappert et al., “Temperture Tuning of an Organic Dye Laser” Applied Physics Letters 13(4):124-126 (Aug. 15, 1968).
Shuster, “Acne: The Ashes of a Burnt Out Controversy,” Acta Derm. Venereol. Suppl. (Stockh), 120:43-46, 1985.
Sigurdsson et al., “Phototherapy of Acne Vulgaris with Visible Light,” Dermatology, 194:256-260, 1997.
Spears et al., “Fluorescence of Experimental Atheromatous Plaques with Hematoporphyrin Derivative,” J. Clin. Invest, 71:395-399 (1983).
Spotswood, “Novel Use of Fractional Lasers for Scarring Improves Quality of Life for Injured Troops”, http://www.usmedicine.com/articles/novel-use-of-fractional-lasers-for-scarring-improves-quality-of-life-for-injured-troops-.html, (Aug. 2012) , U.S. Medicine ISSN: 0191-6246. 4 pages.
Strauss et al., “Skin Lipids and Acne,” Annu. Rev. Med., 26: 27-31, 1975.
Sumian et al., “A new method to improve penetration depth of dyes into the follicular duct : . . . ,” J. Am. Acad. Dermotol., 41(2) Part 1:172-175, 1999.
Tarasov, L. V., Laser Physics, Translated from Russion by Ram S. Wadhwa, MIR publishers, Moscow, pp. 178-181, Chapter 2, 1983.
Tarijian, et al., “Fractional abalative laser skin resurfacing: A review”, Journal of Cosmetic and Laser Therapy, 13:262-264, ISSN 1476/4172. Informa UK Ltd. Sep. 2011, 3 pages.
Vasily, et al., “Non-Ablative Fractional Resurfacing of Surgical and Post-Traumatic Scars”, Journal of Drugs in Dermatology, 8(11):998-1005, Nov. 2009, 8 pages.
Watson, G. M., MS, “Minimally Invasive Therapies of the Prostate,” Minimally Invasive Therapy, 1:231-240 (1992).
Wei Tech Ang et al., “Design of All-Accelerometer Inertial Measurement Unit for Tremor Sensing in Hand-Held Microsurgical Instrument,” 2003 IEEE International Conference on Robotics and Automation (vol. 2), Taipei, Taiwan, Sep. 14-19, 2003.
Wei Tech Ang et al., “Kalman Filtering for Real-Time Orientation Tracking of Handheld Microsurgical Instrument,” 2004 IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS), Sendai, Japan, Sep. 28-Oct. 2, 2004.
Wilson, S.W., “Passive Alignment of a Semiconductor Laser to an Optical Fiber,” Universirty of Maryland, Master's Thesis (1995).
Winters, B.H. et al., “Photochemical Products in Coumarin Laser Dyes,” Laboratory for Physical Sciences, College Park, MD, 8-26-74.
Yang et al., “Hybrid optoelectronics: A polymer laser pumped by a nitride light emitting diode,” Applied Physics Letters 92, Jan. 23, 2008.
Zapka et al. “Pulse Slicing and Pockels Cell Shutters,” J. Phys. E: Sci, Instrum., vol. 15 (1982).
Mang, “Effect of Soft Laser Treatment on Wound Healing in the Hamster Oral Mucosa,” American Society for Laser Medicine and Surgery Abstracts, Chapters 25, pp. 5-8.
Related Publications (1)
Number Date Country
20090024193 A1 Jan 2009 US
Provisional Applications (1)
Number Date Country
60389871 Jun 2002 US
Continuations (1)
Number Date Country
Parent 10465137 Jun 2003 US
Child 12032004 US